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Abstract 
Preventing and treating influenza virus infection remains challenging. Influenza is a 
considerable cause of morbidity and mortality all around the world. Programmed cell 
death is deeply related to different aspects of Influenza A Virus (IAV) 
infection.  Subsequent to efficient antigen clearance, it is crucial that excessive cells are 
deleted by apoptosis to maintain cell homeostasis. c-FLIP is an inhibitor of death 
receptor-mediated apoptosis, of which three isoforms have been characterized so 
far. While the isoforms c-FLIPL and c-FLIPS are well characterized, the function of c-
FLIPR remains poorly understood. To study the regulation of the extrinsic pathway of 
apoptosis by c-FLIPR, we employed transgenic mice that constitutively express murine 
c-FLIPR in all hematopoietic cells, called vavFLIPR mice. In the steady state, transgenic 
mice had normal immune cell numbers. However, when challenged with influenza virus 
more weight loss and higher concentrations of IFN-γ and TNF-α were observed at the 
peak of infection. Moreover, a higher viral load was detected in vavFLIPR mice at the 
peak of infection. Analysis of immune cells during IAV infection indicated that 
although the frequency and the absolute cell number of most of the immune cells were 
similar, vavFLIPR mice have a higher number of NK cells at the peak of Infection. 
Natural killer (NK) cells play a pivotal role in immune response against IAV infection. 
The exact role of NK cells in IAV infection is not clear since both protective and 
immunopathogenic roles were reported. To investigate the influence of a higher number 
of NK cells on host outcome during influenza infection, vavFLIPR and WT mice were 
treated with Anti-Asialo-GM1 to deplete NK cells in vivo prior to and during influenza 
infection. Since the differences in viral load disappeared, it was concluded that NK cells 
contribute to a higher viral load in vavFLIPR mice at the peak of IAV infection. Finally, 
it was demonstrated that influenza virus can directly infect and replicate in primary 
murine NK cells. It is likely that influenza A virus targets and kills NK cells, in order to 
evade the NK cell innate immune defense. In turn, however, preventing NK cell 
apoptosis may provide a reservoir for influenza virus to replicate more efficiently. 
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Zusammenfassung 
Influenza-Infektionen tragen weltweit zur Morbidität und Mortalität bei. Influenza-
Infektionen zu verhindern und zu behandeln ist noch immer eine große medizinische 
Herausforderung. Der programmierte Zelltod ist eng mit verschiedenen Aspekten der 
Influenza A Virus (IAV) Infektion verbunden. Nachdem das Antigen erfolgreich 
beseitigt wurde, ist es erforderlich, dass überschüssige Immunzellen durch Apoptose 
entfernt werden, um die Zell-Homöostase zu erhalten. c-FLIP ist ein Inhibitor der 
Todesrezeptor-gesteuerten Apoptose. Drei verschiedene Isoformen von c-FLIP wurden 
bis jetzt beschrieben. Während die Isoformen c-FLIPL und c-FLIPS sehr gut untersucht 
sind, ist über die Funktion von c-FLIPR bisher nur wenig bekannt. Um die Regulation 
des extrinsischen Signalwegs der Apoptose durch c-FLIPR zu untersuchen, wurden 
transgene Mäuse genutzt, die das murine c-FLIPR konstitutiv in allen hämatopoetischen 
Zellen exprimieren. Im stationären Zustand zeigen diese Tiere eine normale Anzahl der 
verschiedenen Immunzellen. Wenn sie jedoch mit IAV infiziert wurden, zeigten sie am 
Höhepunkt der Infektion einen höheren Gewichtsverlust und höhere Konzentrationen 
der inflammatorischen Zytokine IFN-γ und TNF-α. Zu diesem Zeitpunkt war auch die 
Virusbelastung in vavFLIPR Mäusen deutlich erhöht. Die Analyse der Immunzellen 
während der IAV Infektion wies darauf hin, dass, obwohl der Anteil und die absolute 
Zellzahl der meisten Immunzellen sehr ähnlich war, die vavFLIPR Mäuse mehr NK 
Zellen am Höhepunkt der Infektion aufwiesen. Obwohl Natürliche Killer (NK) Zellen 
ein entscheidender Bestandteil der Immunantwort gegen IAV Infektion sind, ist deren 
genaue Rolle bei der IAV Infektion noch nicht geklärt, da sowohl eine schützende als 
auch eine immunpathologische Rolle beschrieben wurden. Um den Einfluss einer 
höheren NK Zellzahl auf die Folgen einer Influenzainfektion für den Wirt zu 
untersuchen, wurden vavFLIPR und Kontrolltiere mit Anti-Asialo Antikörper GM1 
behandelt, um NK Zellen in vivo vor und während der Influenzainfektion zu depletieren. 
Da die Unterschiede in der Viruslast verschwanden, wurde geschlussfolgert, dass NK 
Zellen zu einer höheren Virusbelastung in vavFLIPR Mäusen während einer IAV 
Infektion beitragen. Schlussendlich wurde gezeigt, dass IAV primäre NK Zellen direkt 
infizieren und sich in diesen replizieren kann. Es ist wahrscheinlich, dass IAV auf NK 
Zellen zielt und diese zerstört, um der NK Zell-basierten Immunantwort zu entgehen. 
Mit der Vermeidung der Apoptose von NK Zellen schafft sich das Influenzavirus ein 
Reservoir für die effiziente Replikation. 
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1. Introduction 
 
1.1. Cell death  
The importance of cell death in tissue homeostasis and embryonic development has 
been demonstrated for many years. So far, several types of cell death have been defined, 
amongst them, there are five main forms: apoptosis, autophagic cell death, necroptosis, 
pyroptosis and necrosis. This division is based on important criteria such as mode of 
cell death (program/accidental), initiators and production of inflammation 1. Apoptosis 
and necrosis are differentiated according to the distinct morphological and biochemical 
characteristics 2. In 1972 Kerr et al., described apoptosis, which illustrates a specific 
morphological pattern of dying cells that is distinct from necrosis. Apoptotic cells are 
characterized by cell size reduction, chromatin condensation, nuclear fragmentation, 
membrane blebbing and formation of apoptotic bodies, which subsequently can be 
phagocytosed 3 (Figure 1). In contrast, swelling of the cytoplasm and organelles, 
enormous oxidative stress, rupture of the plasma membrane and release the intracellular 
contents are the main necrosis specifications 4. 
Autophagy is a fundamental catabolic mechanism that is evolutionarily conserved 5. It is 
a self-digestive process where metabolites are recycled in the cells. Upon induction of 
autophagy, double-membrane autophagosomes sequester organelles or a part of the 
cytosol. Autophagosomes go through a series of maturation processes, then they are 
delivered to the endosomal lumen. When an endosome fuses with an autophagosome, 
the product is called amphisome 6–8. Upon fusion of lysosomes to amphisomes, the 
internal contents are degraded 9.  
Recent studies show some forms of necrosis which are regulated on the molecular level 
similary to apoptosis. This regulated necrosis was named necroptosis to discriminate 
between the regulated forms and uncontrolled necrosis 10,11. Another highly 
inflammatory form of programmed cell death is pyroptosis, which is triggered by 
different pathological stimuli such as stroke and cancer. Pyroptosis has a pivotal role in 
controlling microbial infections. Pyroptosis features include rapid plasma membrane 
rupture and release of pro-inflammatory intracellular contents, which is in contrasts to 
apoptosis 12. Unlike passive cell death, all active forms of cell death are tightly 
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regulated. Any variation in the physiologic harmony between cellular proliferation and 
cell death may lead to malignant diseases 13. 
 
Figure 1. Forms of cell death. Cells death can happen in multiple forms. Type I 
(apoptosis), Type II (autophagic cell death) and Type III (necrosis), showed in (left), 
(right) and (middle) of the picture respectively. The apoptotic cell shrinks, DNA is 
fragmented and the membrane blebs. Further along, apoptotic bodies are formed to 
facilitate phagocytosis. Autophagic cells include cell material into autophagosomes, 
while necrosis refers to vacuolation of the cytoplasm, plasma membrane rupture and 
subsequent loss of intracellular contents, which induce inflammation around the dying 
cell. 
 
1.2. Apoptosis 
Apoptosis is a complex, tightly regulated series of cellular events that is essential for 
multicellular organisms to eliminate undesirable cells during development, maintenance 
of tissue homeostasis, and immune system reactions. Dysregulation of apoptosis can 
lead to malignant disease, including cancer and autoimmune diseases 14,15. Moreover, 
the role of apoptosis is substantial in the immune response against viral and bacterial 
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pathogens by the elimination of infected cells before pathogens spread to other cells 4,16. 
There are two main pathways which result in apoptosis, the intrinsic or mitochondrion-
initiated pathway and the extrinsic or cell surface death receptor-mediated pathway 17. 
In both pathways, there are signals that activate the family of cysteine proteases 
(caspases) that act as proteolytic machinery. The extrinsic pathway (the death receptor 
pathway), is activated by binding of death receptors (DRs) which exist on the cell 
surface. The intrinsic (mitochondrial) apoptotic pathway is activated by different cell 
stressors such as DNA damage, pH alteration, UV radiation or growth factor withdrawal 
18. 
1.2.1. Caspases – mediators of apoptosis 
Caspases, cysteine-aspartic proteases or cysteine-dependent aspartate-specific 
proteases, play a fundamental role in apoptosis. Up to now, 11 murine caspases (caspase 
1, 2, 3, 6, 7, 8, 9, 11, 12, 14 and 16) and 12 functional human caspases (caspase 1-10, 14 
and 16) have been described 19,20. According to their function, caspases are categorized 
into two groups, one of which is involved in the apoptotic action (caspases 2, 3, 6, 7, 8, 
9 and 10), and the other is related to inflammation (caspases 1, 4, 5, 11 and 12). The 
apoptotic caspases are further divided into the initiator and effector caspases. The 
initiator caspases consist of caspases 2, 8, 9 and 10, and the effector caspases are 
caspase 3, 6 and 7. Initially, all the caspases are produced as inactive single chain 
polypeptide precursors (zymogen). Caspases contain three structural domains, a N-
terminal pro-domain and two protease domains namely a large subunit (p20) and a 
small subunit (p10) with a cleavage site that is between the large and small subunits 21. 
The N-terminal domain in the initiator caspases, which is crucial for protein 
interactions, consisting of a caspase recruitment domain (CARD) or death effector 
domains (DED). In the initial step of activation, these domains mediate dimerization or 
binding to larger complexes. The initiator caspases are activated with homodimerization 
of the caspase monomers 22. Caspases are recruited to the death inducing signaling 
complex through the interaction of adaptor proteins with CARD or DED domains on 
initiator caspases 23. Homodimerization of caspases leads to auto-proteolytic cleavage of 
the bond between the small and the large subunits, and subsequently cleavage between 
the pro-domain and the large subunit 21,24. On the other hand, the effector caspases 
contain shorter pro-domains and form inactive pro-caspase dimers. Effector caspases 
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can get activated by activated initiator caspases via proteolytical cleavage of the linker 
between large and small subunits. The activated effector caspases can then cleave and 
activate other effector caspases, resulting in a caspase cascade, as well as their other 
physiological substrates 21,25. 
 
 
Figure 2. Domain organization of caspases. Three main groups of caspases are 
presented. Group I: apoptosis initiator caspases. Group II: apoptosis effector caspases.  
Group III: inflammatory caspases. The caspase activation recruitment domain (CARD), 
the death effector domain (DED), the large (p20), and the small (p10) catalytic subunits 
are indicated. 
 
1.2.2. Perforin/granzyme B pathway 
In the granzyme B pathway, perforin and granzyme B are released by cytotoxic T 
lymphocytes (CTL) and Natural Killer (NK) cells, which conjugated to the target cells 
such as virus-infected cells and tumor cells 26. Perforin creates large transmembrane 
pores that mediate the diffusion of serine proteases, known as granzymes into the target 
cell cytosol 27. Granzymes then mediate apoptosis by direct activation of caspase 3 or 
particularly cleavage of Bid and initiation of the intrinsic pathway of apoptosis of the 
target cell 28. Afterward, cytotoxic lymphocytes are detached from the dying cell 29,30. 
1.2.3. The intrinsic pathway of apoptosis  
Several non-receptor-mediated stimuli such as DNA damage, free radicals, toxins and 
radiation can initiate the intrinsic pathway of apoptotic. Following stimulation, 
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the intrinsic intracellular signals are produced, approach the mitochondria and impact on 
the function and integrity of it 31. The main regulators of this pathway are Bcl-2 (B-cell 
lymphoma 2) family proteins. All proteins which belongs to the Bcl-2 family contain 
Bcl-2 homology (BH) domains.  Based on their function and number of the BH 
domains, the Bcl-2 family is divided into three groups 32,33. The first group contains the 
anti-apoptotic proteins Bcl-2, Bcl-2-like protein 2 (Bcl-w), B cell lymphoma extra-large 
(Bcl-xL), myeloid cell leukaemia 1 (Mcl-1) and Bcl-2-related protein A1 (A1). These 
proteins contain all four BH domains (BH 1-4) and are located in the outer 
mitochondrial membrane, where the dimerization with other Bcl-2 proteins occurs. The 
two remaining groups are pro-apoptotic. The second group comprise Bcl-2-associated x 
protein (Bax), Bcl-2 antagonist killer 1 (Bak) and Bcl-2-related ovarian killer (Bok) 32. 
In this group, proteins contain BH domains 1-3. In order for cells to survive, Bax and 
Bak must constantly be inhibited by anti-apoptotic Bcl-2 members. Alternatively, when 
apoptosis is needed, Bax and Bak mediate the permeabilization of the outer 
mitochondrial membrane (OMM), which results in the release of apoptogenic molecules 
such as cytochrome c from the mitochondria 34. Release of the cytochrome c induces the 
formation of the wheel-like structure complex, which contains several molecules of 
cytochrome c, apoptotic peptidase activating factor 1 (APAF1) and caspase 9 
(apoptosome) 35,36. Active caspase 9 can mediate activation of the executioner caspases 
3 and 7 that cause apoptosis 37. The last group contains the BH3-only proteins, which, 
as defined by the name, only have the BH3 domain. The proteins, which belong to this 
group are Bcl-2 antagonist of cell death (Bad), Bcl-2-interacting killer (Bik), Bcl-2 
interacting domain death agonist (Bid), Harakiri (Hrk, also known as death protein 5, 
(DP5), Bcl-2-interacting mediator of cell death (Bim), Bcl-2 modifying factor (Bmf), 
Noxa, p53-upregulated modulator of apoptosis (Puma) and Mcl-1 ubiquitin ligase E3 
(Mule) 38. 
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Figure 3.  The Bcl-2 family proteins. The proteins are divided into the anti-apoptotic 
Bcl-2 homologues, the effector proteins, and the pro-apoptotic BH3-only proteins. 
 
1.2.4. Activation of Bak and Bax 
During apoptosis, Bax and Bak are subjected to conformational changes and 
oligomerize at discrete sites on the mitochondria 39. The oligomerization of Bax and 
Bak results in the permeabilization of the mitochondrial membrane and releases pro-
apoptotic molecules, which lead to apoptosis 40. Cells that lack both Bax and Bak, but 
not cells lacking only one of them, are totally resistant to tBID-induced cytochrome c 
release and apoptosis 41. Notably, double deficient cells are resistant to various intrinsic 
apoptotic stimuli. Because of the pivotal role in the induction of mitochondrial 
apoptosis, Bax and Bak should be tightly regulated by other members of the Bcl-2 
family 42. 
1.2.5. The extrinsic pathway of apoptosis 
Binding extracellular death ligands to their transmembrane death receptors (DRs) can 
initiate extrinsic apoptosis. Death receptors belong to the tumor necrosis factor (TNF) 
receptor superfamily 43. TNF superfamily consists of the number of plasma membrane 
receptors with an important homology in their extracellular domain, defined by the 
presence of up to six cysteine-rich domains (CRD), which describe their ligand 
specificity 44–46. Among them, Fas (CD95/APO-1), TNF-receptor 1 (TNF-
R1/p55/CD120a), TNF-related apoptosis-inducing ligand receptor 1 [TRAIL-R1/Death 
Receptor 4 (DR4)], and TRAIL-receptor 2 (TRAIL-R2/DR5/APO-2/KILLER), Death 
Receptor 3 (DR3/APO 3/TRAMP/WSL-1/LARD) and 6 (DR6) have been extensively 
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studied 47,48. Notably, an intracellular 80-amino acid motif, called death domain is 
indicative for the death receptors and has an important role in transducing signals upon 
activation by the respective death ligand 49. Apoptosis can be initiated by various death 
ligands such as CD95 ligand. The death receptor CD95 is activated by its cognate 
ligand, binding of which results in oligomerization and activation of the intracellular 
death domain. Ligand binding induces binding of the adaptor molecule FADD (Fas-
associated-protein with DD) to the death domain of the CD95 receptor. Afterwards, 
procaspase 8 or 10 is recruited to the platform via their death effector domain and 
dimerization occurs.  The death receptor, the adaptor molecule FADD and procaspase 8 
or 10 form a multi protein complex called death-inducing signaling complex (DISC) 50. 
The induced proximity initiates activation and autoproteolytical cleavage of the 
caspases in the DISC. Active caspase 8 and 10 can further activate effector caspases, 
which cleave of the numerous substrates and cause apoptosis 51. TNF is a 
transmembrane protein, which can be further processed into a soluble form (sTNF) 52. 
TNF can apply its function via two receptors, TNF receptor 1 (TNFR1) and TNFR2. 
TNFR1 is mainly associated with inflammation and tissue degeneration. However, 
TNFR2 is predominantly involved in tissue regeneration and immune modulation 53. 
Notably, sTNF and Membrane-bound TNF (memTNF) both can activate TNFR1 
whereas TNFR2 can only get fully activated by memTNF 54. Deregulation of TNF 
expression and signaling can lead to chronic inflammation, which can mediate the 
development of autoimmune diseases and tissue damage 55. 
1.2.6. Cross talk between intrinsic and extrinsic pathway of apoptosis 
The extrinsic pathway can crosstalk to the intrinsic pathway by caspase 8-mediated 
cleavage of BID 54. In type I cells, high levels of DISC formation boost high amounts of 
active caspase 8, which can activate effector caspases 55,56. In contrast, type II cells 
assemble low amounts of DISC and therefore, less active caspase 8 is formed 56. Since 
this amount of active caspase 8 is not enough to directly process caspase 3, hence 
amplification of the death receptor signal is needed to induce apoptosis. This 
amplification occurs by caspase 8 mediated processing of the BH3-only protein Bid 57. 
The anti-apoptotic Bcl-2 family members are inhibited by the active protein truncated 
Bid (tBid), which results in permeabilization of the outer mitochondrial membrane with 
Bax and Bak proteins 58,59. Because of the disruption in mitochondrial integrity, 
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cytochrome c is released into the cytosol and induces the formation of the apoptosome 
and activation of caspase 9, which mediates activation of caspase 3 and caspase 7 
causing apoptosis. In type II cells, overexpression of the Bcl-2 or Bcl-XL can block 
death-receptor-mediated apoptosis, which demonstrates the necessity of the interplay 
between the extrinsic and intrinsic apoptosis pathways in these cells 56. 
 
 
Figure 4. The death receptor superfamily and their ligands. The death and decoy 
receptors are illustrated at the bottom, with the extracellular cysteine-rich domains in 
blue and death domains (DDs) in green. TNF-R1 (p55/p60 TNF-R), CD95 (Fas, APO-
1), death receptor 3 (DR3, TRAMP), TRAIL-R1 (DR4), TRAIL-R2 (DR5) DcR1, 
DcR2 and OPG and DR6 are activated by their respective ligands, which are indicated 
in orange. 
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Figure 5. The extrinsic and intrinsic apoptosis pathways. The connection of the intrinsic 
(mitochondrial) and death receptor pathways in the caspase cascade system is indicated. 
APAF1, apoptotic peptidase activating factor 1; Bak, Bcl-2 antagonist/killer 1; Bax, 
Bcl-2-associated X protein; Bcl-2, B-cell leukemia/lymphoma 2; BID, BH3-interacting 
domain death agonist; BH, Bcl-2 homology domain; DIABLO, diablo homolog 
(Drosophila); DISC, death-inducing signaling complex; FAS, tumor necrosis factor 
receptor superfamily member 6; FASL, Fas ligand (TNF superfamily, member 6); IAP, 
inhibitor of apoptosis. 
 
1.2.7.  FLICE-inhibitory proteins (FLIPs) 
In 1997 the cellular FLICE-inhibitory protein (c-FLIP) was reported by several groups 
as a cellular homologue to viral FLIPs 57,58. Although thirteen c-FLIP splice variants 
have been identified, presently only three proteins have been isolated, namely c-FLIP 
long (c-FLIPL), c-FLIP short (c-FLIPs) and c-FLIP Raji (c-FLIPR), which have 55 kDa, 
26 kDa and 24 kDa molecular weight, respectively 56,59. c-FLIPL is structurally similar 
to pro-caspase 8 consisting of two death effector domains (DED) at the N-terminus and 
the C-terminal caspase-like domains. However, because of the substitution of several 
amino acids in the active site, including the catalytic residues His-237 and Cys-285, it is 
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catalytically inactive 60. The structures of c-FLIPS and the viral FLIP (v-FLIP) proteins 
are comparable 61. However, following the two DEDs of c-FLIPS, there are 20 amino 
acids that are essential for its ubiquitination and targeting for proteasomal degradation 
62–64. c-FLIPR also consists of two DEDs but lacks the additional carboxy (C)-terminal 
amino acids that are present in c-FLIPS. C-FLIP is expressed abundantly in many 
tissues, for instance in neurons, cardiac myocytes, skeletal muscle, kidney, epithelial 
cells, macrophages, T and B cells  65,66. c-FLIP proteins control death receptor-mediated 
apoptosis by interfering with caspase 8 activation 67,68. C-FLIPS inhibits DR-mediated 
apoptosis by preventing processing of caspase 8 at the DISC 56,69. C-FLIPL has a 
controversial role and acts in a pro or anti-apoptotic manner, leading to activation or 
inhibition of apoptosis 70. In the presence of high levels of c-FLIPS or c-FLIPR or strong 
death receptor stimulation, c-FLIPL works like a pro-apoptotic molecule whereas high 
c-FLIPL levels inhibit apoptosis 
70. 
 
 
Figure 6. c-FLIP proteins regulate caspase 8 activity 63,71,72. Caspase 8 homodimers 
initiate activation and autoproteolytical cleavage of the caspase 8 molecules, which  
lead to apoptotic signaling, whilst the short c-FLIP isforms block apoptosis 73. 
Heterodimers of caspase 8 and c-FLIPL result in activation of caspase 8, but only partial 
cleavage and therefore only limited caspase 8 activity. Adapted from reference 74 
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Figure 7. Structure of c-FLIP proteins. The v-FLIP proteins are expressed in γ-
herpesviruses such as Kaposi’s-sarcoma-associated human herpesvirus-8 (HHV8), 
herpesvirus saimiri and equine herpesvirus-2 as well as in molluscipoxviruses. Three 
isoforms of cellular caspase 8 (FLICE)-inhibitory protein (cFLIP) are known: cFLIPlong 
(cFLIPL) cFLIPshort (cFLIPS) and cFLIP Raji (cFLIPR). All viral and cellular FLIP 
proteins include tandem DED domains. Adapted from reference 16 
 
1.3.  Biology of influenza virus and replication 
Influenza viruses are negative-sense single-stranded, segmented RNA genome viruses, 
which belong to the family of orthomyxoviridae. The family of orthomyxoviridae 
includes Influenza virus A, Influenza virus B, Influenza virus C, Isavirus and 
Thogotovirus. Antigenic differences in nucleoproteins and matrix proteins have been 
used to distinguish Influenza A virus, Influenza B virus and Influenza C virus. In 
addition, further classification of influenza A viruses (IAV) is based on two important 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) 75,76. 
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1.3.1.  Influenza A virus 
Influenza is a respiratory pathogen, which causes considerable morbidity and mortality 
all around the world, resulting in 3-5 million infections and 250,000-350,000 deaths 
annually 77,78. All age groups can get infected by influenza. However, some people like 
the elderly or pregnant women, are more susceptible to get flu complications that result 
in hospitalization and sporadically even death 79,77. There are two important mechanisms 
by which influenza A viruses change their antigenic properties. These are commonly 
referred to as “antigenic drift” and “antigenic shift 80,81. Influenza can change 
substantially with recombination (antigenic shift). Therefore, the host has no protective 
immunity, which results in increasing influenza mortality rate even among healthy 
young adults. Moreover, because of low fidelity of the RNA polymerase and the lack of 
proofreading mechanism, antigenic drift (mutation) happens in the IAV virus genome 
frequently 82. Recombination of RNA or antigenic shift happens when two or more 
different strains of the virus combine and form a new subtype, which is showing a 
mixture of the surface antigens from each strain. As a consequence of the antigenic shift 
and antigenic drift, the potential host will be without protective immunity, which 
increases dramatically the morbidity and mortality rates of influenza infection. 
1.3.2.  Viral genome organization  
The influenza A genome is approximately 13.6 kb in size and comprises eight viral 
RNA (vRNA) segments which encode 11 proteins including: matrix 1 (M1), matrix 2 
(M2), nucleoprotein (NP), non-structural protein 1 (NS1), non-structural protein 2 
(NS2), polymerase acidic protein (PA), polymerase basic protein 1 (PB1), polymerase 
basic protein 2 (PB2), and polymerase basic protein 1-F2 (PB1-F2) hemagglutinin 
(HA), neuraminidase (NA)83.  HA and NA are two surface glycoproteins that have 
substantial roles in viral replication and pathogenicity. Eighteen IAV HA (H1-H18) and 
eleven IAV NA (N1-N11) subtypes have been identified so far 84,85. Hemagglutinin is a 
membrane glycoprotein (MW 61.5 kDa monomer) and the main surface antigen of the 
influenza virus. Synthesis of HA occurs in the rough endoplasmic reticulum of the 
infected cells 86,87. This protein has a homotrimer structure, which forms a spike shape. 
HA has two main functions. Helping the virus to attach to the cell, by binding to host 
sialic acid-containing receptors and then intermediating membrane fusion between the 
endocytic vesicle and the viral membrane during viral penetration 88. Neuraminidase 
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intercedes enzymatic cleavage of the viral receptor, which results in release of the newly 
assembled virus. The molecular mass of the monomer is 60 kDa. In general, there is 
four times more HA than NA on the surface of the influenza A virus, which makes the 
HA glycoprotein the prominent part of the external structure of the influenza A virus 
89,90.  
 
Figure 8. Morphology and genome structure of Influenza A genome. The influenza A 
genome consists of 8 negative-strand RNA segments. The hemagglutinin protein (HA) 
and neuraminidase (NA) that are present on the surface of the viral envelope are used to 
classify influenza A into different subtypes. 
 
Replication of the influenza A virus is a multi-step process. In the first step of viral 
replication cycle, the virus attaches and enters the host cell. This initial step is followed 
by fusion of the viral and endosomal membrane, uncoating, transcription, protein 
synthesis, assembly and finally exiting of the host cell 91. The main target of the 
Influenza virus is the epithelial cells. This attachment happens through sialic acid 
receptors on the surface of the target cells in the airway. The attached virus particle 
enters the host cell through receptor-mediated endocytosis 92. The low pH in the 
resulting endosome leads to a conformational change in the hemagglutinin protein, 
which mediates the fusion of viral and endosomal membranes. The low pH also 
increases the proton flux into the virus via the M2 ion channel. The M2 ion channel 
pumps protons into the endosomes, therefore dissociating the vRNPs from M1 matrix 
proteins and releasing the viral ribonucleoproteins into the cytoplasm and then 
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transporting them into the cell nucleus 93. In the nucleus (-) sense influenza-viral 
RNAs are used as a template for the RNA-dependent RNA polymerase complex to 
generate two different kinds of RNA. Viral messenger RNA (mRNA) is produced for 
the synthesis of viral proteins, and complementary RNA (cRNA) is transcribed to 
produce genomic vRNA 75. The influenza virus polymerase complex expresses PB2, 
PB1 and PA subunits and use 5´-capped primers from host mRNA to transcribe viral 
genomic RNAs into mRNA. The viral mRNA is transported back to the cytoplasm for 
translation into viral proteins. HA, NA and M2 envelope proteins are translated on the 
membrane-bound ribosomes. Afterwards, these proteins are transferred to the 
endoplasmic reticulum (ER), glycosylated in the Golgi apparatus and transported to the 
cell membrane. The other viral proteins (M1, PB1, PB2, NP, PA, NS1 and NS2) are 
transported to the host nucleus. In the host nucleus, there are newly synthesized vRNA 
available. This vRNA is coated with M1 protein and transferred to the plasma 
membrane 94,95. A high amount of M1 protein at the cytoplasmic side of the lipid 
bilayer, mediates viral budding. Finally, the cellular membrane covers the nucleocapsid 
and the virions exit the cell 96. 
 
Figure 9. Replication of influenza A virus. After attachment to the target cell receptor 
containing sialic acid, the virus particle goes through the processes, consisting of fusion, 
endocytosis, uncoating, and subsequently replication by the RNA polymerase. 
Afterwards, surface protein-coated envelope forms around the genome to produce a 
complete virion, which can then leave the cell and infect other cells. 
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1.4. Innate immune response to IAV 
The innate and adaptive immune system work together to clear the viral infection. In 
recent years, appreciation of the role of innate immunity in defense against influenza A 
virus (IAV), has grown exponentially 97–100. Innate immune responses are not specific to 
a particular pathogen. However, it plays an important role as the first line of defense. 
Innate immunity against influenza consists of physical barriers and innate cellular 
immune responses 101. Skin and lung are the only organs that directly contact the 
external environment. The airway tract mucosa has a substantial role in protecting the 
lung from pathogens that have been inhaled 102. If the virus successfully passes the 
mucous layer, it will bind and attack the respiratory epithelial cells 103. Henceforth the 
virus can spread to immune and non-immune cells. Infected cells present the viral RNA 
which is called pathogen-associated molecular patterns (PAMPs)  104. Recognition of 
(PAMPs) by pattern recognition receptors (PRRs) on the innate immune cells, mediates 
signaling cascades. The signaling cascades result in the production of interferons 
(IFNs), cytokines and chemokines 105. Three different classes of PRRs have been shown 
to play a role in recognition of an influenza A infection and the induction of an IFN 
response: Toll-like receptors (TLRs), retinoic acid inducible gene-I (RIG-I) receptors 
and the nucleotide oligomerization domain (NOD)-like receptor family pyrin domain 
containing protein 3 (NLRP3) inflammasome 106–108. 
TLRs are the first receptors that were identified as having the ability to sense the viral 
nucleic acids 109. TLR7 is an intracellular receptor that recognizes single-stranded viral 
RNA (ssRNA) that are taken up into the endosome 110. Double-stranded viral RNA 
(dsRNA) is recognized by another intracellular receptor TLR3, which leads to the 
production of type I IFN and proinflammatory cytokines 111,112. Viral surface 
glycoproteins, HA and NA are recognized by TLR2 and TLR4, which are present on the 
cell surface 113. RIG- I recognize the 5ʹ-triphosphate viral ssRNA that is generated after 
viral replication. At the later stage of infection, the uncapped 5ʹ-triphosphate viral 
ssRNA, which was generated after viral replication, is recognized by RIG-I in the 
cytoplasm 114,115. The intracellular recognition by the PRRs results in the production of 
interferons (IFNs), cytokines and chemokines, which leads to transcription of hundreds 
of interferon-stimulated genes (ISGs) that significantly limit viral infection of target 
cells 105. However, by using NS1 protein, which interferes with the RIG-1 system, the 
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virus can inhibit the type I interferon response. Previous studies have shown that the 
inflammasome responds to influenza virus 116. There are two main signals responsible 
for activation of the inflammasome. The first signal is produced as a result of the 
presence of foreign particles in the airway epithelial cells. This signal, which 
constitutively stimulates the NLRP3 inflammasome, is called signal 1 117,118. The first 
signal mediates the production of pro-IL-1β and pro-IL-18. Signal 2 can be provided 
with ssRNA of IAV or IAV M2-induced proton flux or PB1-F2 aggregates in lysosomes 
119,120,121. Signal 2 can activate the inflammasome and mediate caspase 1 activation. 
Caspase 1 activation is necessary for the cleavage of the pro-IL-1β and pro-IL-18 into 
their active forms 122,123. 
Different immune cells are involved in the innate immunity against influenza. The high 
level of cytokines and chemokines such as type I IFN, IL-1 and IL-6 at the site of 
infection attracts innate immune cells consisting of natural killer (NK) cells, 
neutrophils, macrophages and dendritic cells 103 . Following IAV infection, neutrophils 
are recruited to the infection area and mediate viral clearance through phagocytosis of 
apoptotic IAV-infected cells and secretion of pro-inflammatory cytokines 124–126. 
Neutrophils also play an important role in regulating IAV-specific CD8 T cells in the 
periphery, which indicates the role of neutrophils in connecting innate and adaptive 
immune responses against IAV 127. Alveolar macrophages (AM) are one of the main 
phagocytic and prominent antigen presenting cells in the lungs. In steady state 
condition, AM are relatively inactive and show regulatory cell phenotypes 128. The 
phagocytic property and cytokine production is relatively low in these homeostatic AM. 
Notably, these AM play a role in the suppression of the induction of the innate and 
adaptive immunity 129,130. During IAV infection, homeostatic AM can get activated and 
converted into extremely phagocytic cells that can produce a solid amount of 
inflammatory cytokines. Moreover, during infection, macrophages are also recruited to 
the lung and assist both innate and adaptive immune responses. Macrophages secrete 
pro-inflammatory cytokines and chemokines such as IL-1, IL-6, IL-8, IL-12, TNFα, and 
IFN-γ. Additionally, they also work as antigen presenting cells to activate the IAV-
specific T cell response 76. Depletion of AM suggested that these cells are crucial in the 
early protection of influenza infection. AM depletion before day three post infection 
causes uncontrolled viral replication and escalates mortality 76. Although neutrophils 
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and macrophages have a substantial role in controlling IAV infection, some studies, 
which illustrate the contribution of macrophages to the “cytokine storm”, which can 
cause morbidity 76. Therefore, these cells can demonstrate both beneficial and 
detrimental roles during IAV infection. 
The role of natural killer (NK) cells in controlling IAV infection have been 
demonstrated for many years 131. NK cells are granular lymphocytes that are part of the 
innate immunity through their natural cytokine and chemokine production 132,133. NK 
cells circulate all over the body. In mice, NK cell frequencies oscillate from 1% to 10% 
in lymph nodes and lung respectively. Notably, the spleen has the largest absolute NK 
cell number 134. As a part of the innate immune response, NK cells have the ability to 
respond immediately to any unusual changes in the host such as infection. Activation of 
NK cells can be regulated by activating and inhibitory receptors, such as inhibitory 
receptors KLRG1, CD94/NKG2-A and 2B4 and activating receptors NKG2D, NKp46, 
and CD16 135. Moreover, in mouse NK cells, the family of lectin-like receptors Ly49 is 
expressed, which act as activating and inhibitory receptors 136. The inhibitory part of 
Ly49 recognizes major histocompatibility complex (MHC) class I. Recognition of MHC 
class I on a target cell by an NK cell produces an inhibitory signal. However, by sensing 
the ligands with the activating receptor, an activation signal is produced. The balance 
between activation or inhibitory signals controls the NK cell activation. In the virally 
infected cell, MHC class I is downregulated, which leads to an increase in sensitivity to 
NK cell-mediated killing. Beside this downregulation, activation of NK cell requires 
signals via activating receptors, which mediate production of cytokines and cytolytic 
activity 137. 
It has been described that NK cells can get activated via binding to HA proteins, which 
are expressed on the surface of IAV-infected cells to the NK receptors NKp44 and 
NKp46 138,139. This activation mediates direct killing of IAV infected cells via a 
perforin/granzyme mechanism, which controls the spread of the virus 140,132.  
Dendritic cells (DCs) belong to the antigen-presenting cells and fundamental mediators 
of immunity and tolerance. Respiratory dendritic cells (rDC) are present in the lung and 
check the airway for any foreign particles. In the steady state, the migration rate of rDCs 
to the lung draining lymph nodes (DLN) is low. However, following IAV infection this 
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migration is accelerated 141. Depending on the viral dose and virus strain this high level 
of migration can continue up to 7 days post infection 138,142. DCs can present the antigen 
via MHC class I and II 143. This antigen can be directly taken up from the infected cell, 
which is called direct presentation or via using the antigen from an apoptotic IAV-
infected cell, named cross-presentation 144. However, the exact source of this antigen 
has been difficult to ascertain.  It has been shown that most of the influenza viruses are 
able to infect DCs and lead to viral protein synthesis, however, infection is generally 
abortive and does not produce infectious particles145. Following infection with IAV, 
DCs mediate production of proinflammatory cytokines and chemokines including type- 
I IFN (IFN-α and IFN-β), IL-6, IL-12, TNF-α, IL-8, IP-10, RANTES and MIP-1β 146. 
 
1.5. Cellular adaptive response 
1.5.1. CD8+ T cell effector functions in the lung 
In the presence of IAV infection, one of the main goals of the immune system is to clear 
the infected epithelial cells by CD8+ T cells 147. CD8+ T cells perform this duty with 
either FasL or perforin/granzyme-mediated mechanisms 148. Around day four post-
infection, the number of influenza-specific CD8+ T cells is increased 149,150. In the lung, 
they expand and accumulate in order to clear the viral infection. Notably, in the absence 
of CD4+ T cells, B cells, and neutralizing antibody, CD8+ T cells can take over and 
control the influenza virus infections, which emphasizes the importance of CD8 cells 
151,152. This hypothesis that CD8+ T cells employ perforin and Fas ligand to initiate 
killing of influenza-virus-infected targets was verified by Topham et al. They illustrated 
that viral clearance was delayed in perforin-/- or Fas-/- IAV infected mice. In these mice, 
pulmonary influenza virus titers were detectable for longer durations. Remarkably 
chimeric mice, which contain perforin-/- CD8+ T cells and Fas-/- respiratory epithelium 
cells showed significantly higher viral load even up to 14 days post infection. However, 
despite lacking both perforin and Fas, some of these mice showed less viral titers on day 
14 compared to day 10 post infection 148. One possible explanation for these data is that 
there might be another mechanism, which CD8+ T cells use for killing the influenza 
infected target cells.  
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1.5.2. CD4+ T cell responses to influenza virus 
In addition to CD8+ T cells, which play an important role during IAV infection, CD4+ T 
cells also provide support in the primary response to IAV infection. Among the plenty 
of activities that CD4+ cells perform, providing potent help for priming of CD8+ T cell 
responses has been shown to be the most important one. Lack of CD4+ T cells results in 
significantly less production of IL-2 and IFN-γ in the lung-draining lymph node and the 
bronchoalveolar lavage 153,154. Although CD4+ T cells and the chemokines that they 
produce are not absolutely essential for controlling the primary infection, the absence of  
CD4+ T cells affect the cytolytic function of the CD8+ T cells, antibody production of B 
cells and memory formation of both CD8+ T cells and B cells 155,156. Moreover, CD4+ T 
cells also provide effector functions and assist with the clearance of the virus during 
primary and memory responses. These CD4+ effector cells employ perforin-mediated 
cytotoxic pathways to ameliorate host survival 157,158. 
1.5.3. Humoral immune response 
IAV infection advocates both a local and systemic humoral response. During influenza 
infection or vaccination activated B cells produce influenza directed antibodies159. This 
humoral response is pivotal for the clearance of the virus in the primary infection as 
well as for long-term immunity 159. It has been shown that there is a correlation between 
the titers of serum neutralizing specific antibody for the HA and NA proteins and 
protective immunity. Anti-HA antibodies can interrupt viral attachment to host cells and 
inhibit receptor-mediated endocytosis 160. Another type of antibodies has been 
described, which is related to the NA protein. This protein is required for the release of 
newly synthesized virions. Antibodies against NA do not neutralize the virus but limit 
the spread of the virus 81,161. 
All natural infections with any strain of influenza virus are able to exploit the long-lived 
antibody-mediated defense against a similar infection 162,163. The humoral response 
against respiratory viruses can be produced locally in the nasal-associated lymphoid 
tissue (NALT) and bronchus-associated lymphoid tissue (BALT) 164,165. By day three 
post infection, DCs, which have migrated from the infection area, present viral antigen 
to B cells in mediastinal lymph node. B cells can also directly take the viral antigens in 
the mediastinal lymph nodes (MLN) or at the site of infection in order to transport it to 
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the lymph nodes 166. Formation of germinal centers, which contains B and T cell zones, 
in BALT support B cell proliferation. Furthermore, in the absence of peripheral 
lymphoid organs such as lymph nodes, spleen and Peyer’s patches, the isolated immune 
response in the BALT could clear influenza infection and results in a small measure of 
protective immunity 167. Both germinal center and extrafollicular B cell responses can 
be derived by Influenza A infection. However, memory B cells and long-lived plasma 
cells are mainly produced by the germinal center reaction 168. 
 
1.6. Aim of the thesis 
Cell fate decisions in response to influenza virus infection have an important role in 
elimination and control of the infection. On the other hand, apoptosis can cause tissue 
damage and multiple organ disfunction at the peak of infection 169. Although many 
aspects of apoptosis have been identified, regulation of apoptosis, especially by c-FLIP 
proteins remains a matter of interest in experimental research 170,171. It has been shown 
that c-FLIP proteins act at the level of the CD95 DISC and that c-FLIPlong and c-
FLIPshort inhibit caspase 8 activation via two different mechanisms 
56. Further studies on 
c-FLIP protein expression in cell lines of various species led to the outstanding 
knowledge that only humans are able to express c-FLIPshort, while the only short c-FLIP 
isoform that other species can express is c-FLIPR 
172
. Although the physiological roles of 
c-FLIPL and c-FLIPS are well characterized, the function of c-FLIPR in the immune 
system is poorly understood. In 2013, Telieps et al., showed that adult vavFLIPR mice, 
in which c-FLIPR was constitutively expressed in all hematopoietic cells, had normal 
numbers of immune cells in the steady condition. However, when challenged with 
Listeria monocytogenes vavFLIPR mice showed better bacterial clearance, less liver 
necrosis and less caspase 3 activation compared with infected wild-type littermates 173. 
Thus, it seems that early apoptosis occurring during Listeria monocytogenes infection is 
restricting bacterial clearance. The death receptor-mediated signaling pathway can 
contribute to the pathology of IAV infection. TNF-α, Fas ligand, and TRAIL are known 
to be death ligands, and recognized by TNFR1, Fas, DR4, and DR5, respectively. In 
lethal IAV infections, elevated expression of these death ligands was reported. 
Impairment in the induction of apoptosis caused by these death ligands can affect the 
morbidity of IAV infection. Viruses infect host cells in order to use cellular proteins and 
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enzymes for replication. For a long time, apoptosis was known as a host defense 
mechanism, which can limit virus replication. However, recent evidence supports the 
hypothesis that viruses have a mechanism to utilize apoptosis and take advantage of it. 
c-FLIP is known as an inhibitor of death receptor-mediated apoptosis. This project aims 
to elucidate the role of c-FLIPR in anti-viral immunity and the consequences of the 
constitutive expression of c-FLIPR for the host and the influenza virus. Additionally, 
this thesis evaluated the contribution of the higher number of natural killer cells during 
influenza virus infection and examined the direct effect of influenza virus on NK cells. 
 
Material and Methods 
22 
 
2. Materials and Methods 
 
2.1.  Materials   
2.1.1. Mice 
The mouse strain vavFLIPR was generated by the transgenic core facility of the 
University of Duesseldorf, Germany from a transgenic construct with murine c-FLIPR 
cDNA in the vector HS21/45 vav-hCD4 174. Mice carrying the transgenic construct were 
backcrossed for more than ten generations to C57BL/6 mice. WT littermates were used 
as control animals. All mice were maintained under specific pathogen free conditions at 
the animal facilities of the Helmholtz Centre for Infection Research. All experiments 
were approved by an external committee according to the national guidelines of the 
animal welfare law in Germany. The protocol used in these experiments has been 
reviewed by an ethics committee and approved by the ‘Niedersächsisches Landesamt 
für Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany’ (Permit 
Number :15042). Genotyping was performed by PCR on tail biopsies using KAPA 
Mouse Genotyping Hot Start Kit (PEQLAB) according to manufacturer’s protocol. 
2.1.2. Influenza A virus 
Original stocks of viruses were obtained from Prof. Dr. Dunja Bruder, University of 
Magdeburg (PR8, A/Puerto Rico/8/34 H1N1). Virus stocks were propagated in the 
chorioallantoic cavity of ten-day-old pathogen-free embryonated chicken eggs for 48 h 
at 37 °C. Viral titer was determined by focus-forming unit (FFU) assay. 
2.1.3.  Chemicals  
Chemicals were purchased from Sigma Aldrich (Munich, Germany) or Roth (Karlsruhe, 
Germany) if not stated otherwise. Phosphate buffered saline (PBS), Tween-20, Bovine 
serum albumin (BSA), N-Acetylated Trypsin (NAT), Penicillin and Streptomycin were 
purchased from Invitrogen, Merck, Sigma-Aldrich and Bulldog Bio.  Ketamine and 
Xylazine for mice anesthesia were ordered from Invesa Arzneimittel GmbH. 
RNAlater® solution was ordered from Qiagen. True Blue substrate was purchased from 
KPL. 
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2.1.4.  Cell culture materials and devices 
Cells were cultured in cell culture flasks, 10 cm dishes, 6-well, 12-well, 24-well, 48-
well or 96-well plates from NUNC – Thermo Scientific (Waltham, MA, USA) in the 
incubator HERAcell 240 i (Thermo scientific) at 37°C, 5% CO2 and 95% air humidity. 
Materials used for handling of cells were: 1.5 ml and 2 ml reaction tubes (Sarstedt, 
Nuembrecht, Germany), sterile 10 µl, 200 µl and 1000 µl pipette tips (Starlab, 
Ahrensburg, Germany), 5 ml, 10 ml and 25 ml pipettes (Sterilin - Thermo Scientific), 15 
ml and 50 ml reaction tubes (Greiner-bio-one, Frickenhausen, Germany), 45 µm and 22 
µm sterile syringe filters (Merck Millipore, Billerica, MA, USA). Centrifuges used were 
5810R from Eppendorf (Hamburg, Germany) and Megafuge 1.0 from Heraeus 
SEPATECH (Osterode, Germany). Cells were handled in sterile hoods SterilGARD® 
III Advance° (The Baker Company, Sanford, ME, USA). Cell numbers were determined 
by Neubauer improved cell counting chambers (BRAND scientific, Wertheim, 
Germany) or CellometerTM Auto T4 (Nexcelom Bioscience, Lawrence, MA, USA). 
2.1.5.  Medium for cell culture 
Reagent Order No. Company 
MEM 31095 31095 GIBCO_Life Technologies 
DMEM 11965 11965 GIBCO_Life Technologies 
RPMI 1640 41965 GIBCO_Life Technologies 
Fetal Calf Serum (FCS) A15-101 PAA (Pasching, Austria) 
Sodium-Pyruvate (100 mm) 11360 GIBCO_Life Technologies 
Non-essential amino acids (100 X) 11140 GIBCO_Life Technologies 
Penicillin / Streptomycin (5µg/ml) 15070 GIBCO_Life Technologies 
β-mercaptoethanol (50 mM) 31350 GIBCO_Life Technologies 
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2.1.6. Solutions 
The frequently used buffers are as follows. 
Buffers Components 
Washing buffer for FFU assay 0.5% Tween-20 in PBS 
Blocking buffer for FFU assay 0.5% Tween-20, 1 % BSA in PBS 
Fixative 4% Formalin in PBS 
Quencher 0.5% Triton X-100, 20 mM Glycine in PBS 
Explant culture medium 
DMEM with 10% FCS, 5% L-Glutamine, 1% 
Penicillin / Streptomycin 
MDCK culture medium 
MEM with 10%FCS and 1% Penicillin / 
Streptomycin 
 
2.1.7.  Influenza A virus antibodies 
In order to detect the virus, the following antibodies were used. 
Antibody Catalogue number Company 
Goat anti-influenza virions (H1N1) 1301 Virostat 
Anti-goat-IgG [H+L] Antibody-HPR 14-13-06 KPL 
 
2.1.8.  Oligonucleotides for PCR 
HPLC-purified oligonucleotides were supplied by Eurofins MWG Operon (Ebersberg, 
Germany). 
Name Sequence (5´-3´) 
UBC fwd AAG AGA ATC CAC AAG GAA TTG AAT G 
UBC rev CAA CAG GAC CTG CTG AAC ACTG 
NP fwd GAG GGG TGA GAA TGG ACG AAA AAC  
Np rev TTC AGG ACG GAC GGA CGG AC 
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2.1.9.  Oligonucleotides for mouse genotyping 
Name Sequence (5´-3´) 
c-FLIP fwd GCC TGA AGA ACA TCC ACA GAA TAG 
SV40 poly A rev CTC ATC AAT GTA TCT TAT CAT GTC 
β-actin fwd TGT TAC CAA CTG GGA CGA CA 
β-actin rev TCT CAG CTG TGG TGG TGA AG 
 
2.1.10.   Flow cytometery devices 
Labelled samples were analyzed on BD LSR Fortessa and BD LSR II by Becton 
Dickinson (New Jersey, USA). Cell purification was performed using FACS Aria II 
(Becton Dickinson) or Moflo (Beckman Coulter, Indianapolis, USA) devices. 
2.1.11.  Flow cytometry murine antibodies 
Reactivity Fluorochrome 
Clone/ 
notation 
Isotype Company 
CD3 V500 500A2 
Syrian Hamster 
IgG2, κ 
BD Biosciences 
CD4 Pacific blue RM4-5 rat IgG2a, κ BioLegend 
CD8 PE/Cy7 53-6.7 rat IgG2a, κ BioLegend 
CD8 APC/Cy7 YTS156.7.7 rat IgG2b, κ Biolegend 
CD335-NKp46 eflur660 29A1.4 rat IgG2a, κ eBioscience 
CD11b Pacific blue M1/70 rat IgG2b, κ eBioscience 
CD11c APC eFluor 780 N418 hamster IgG eBioscience 
CD19 PerCP Cy5.5 1D3 rat IgG2a, κ eBioscience 
CD49b APC Dx5 rat IgM, κ eBioscience 
CD62L PerCP Cy5.5 MEL-14 rat IgG2a, κ eBioscience 
CD95 PE Jo-2 hamster IgG2, λ2 BD Biosciences 
F4/80 PE BM8 rat IgG2a, κ eBioscience 
Ly6C APC HK1.4 rat IgG2c, κ Biolegend 
Ly6G PE/Cy7 1A8 rat IgG2a, κ Biolegend 
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2.2. Methods 
2.2.1. RNA isolation 
Total RNA was prepared from lungs using the RNeasy Midi kit (Qiagen, Germany) 
following the manufacturer’s protocol 
2.2.2. Reverse transcription and Quantitative real-time polymerase chain reaction 
(qRT-PCR) 
PR8 and mock-infected mice were euthanized by CO2 asphyxiation; heart blood was 
taken (for hematological analysis) and each entire lung was extracted and immediately 
stored in RNAlater reagent following Qiagen’s instruction. For each group, 5-7 mice 
were prepared as independent biological replicates. Total RNA from the lung was 
prepared according to the detailed protocol from RNeasy Mini Kit (Qiagen) including 
an on-column genomic DNA digestion step (Qiagen’s instruction). The concentration of 
these materials was measured by Nanodrop 2000c (Thermo Scientific). 100 ng of 
purified RNA were used as template to generate a complementary DNA (cDNA) strand 
by means of RevertTM Premium First Strand cDNA Synthesis Kit (Thermo Scientific). 
NP primers were used for RNA transcription according to supplier protocol. cDNA was 
used as a template for real-time PCR using SYBR Green (Roche). Ubiquitin-
conjugating enzyme E2D 2A (UBC) was used as a housekeeping gene for 
normalization. qPCR was implemented in a Roche LightCycler® Real-Time device 
using Roche FastStart SYBRgreen Master (Roche, #04673484001). Measurements were 
run in duplicates in the LightCycler 96 system using the following primers (NP) (5′-
GAG GGG TGA GAA TGG ACG AAA AAC and 3′-CAG GCA GGC AGG CAG GAC 
TT). Incubation were done in peqSTAR thermocycler. 
 
Time Temperature Function Cycles # 
1 minute 95 °C Preincubation 1 
10 seconds 95 °C Single   
10 seconds 60 °C Mode of  45 
10 seconds 72 °C Acquisition   
10 seconds 95 °C Continuous   
60 seconds 65 °C Mode of  1 
1 second 97 °C Acquisition   
Material and Methods 
27 
 
2.2.3. Photometric determination of DNA/RNA concentration 
DNA/RNA concentrations were measured with the Nanodrop 2000c (Thermo 
Scientific). The Beer-Lambert equation is used to correlate the calculated absorbance 
with concentration. 
c = ε x d x E-1 
c = concentration (mol/l)  
ε = coefficient of extinction (M-1 x cm-1)  
d = density of the cuvette (cm) 
E = extinction 
d = the pathlength in cm (cm) 
2.2.4. Influenza virus isolation in MDCK cell  
MDCK cells were incubated in DMEM with 10% FCS, 5% L-Glutamine, 5% P/S and 
1% NEAA at 37ºC in 5% CO2 incubator for 1-2 days. Then growth medium was 
replaced with infection medium (MEM containing 2.5 μg/ml NAT (N-Acetylated 
Trypsin, Sigma), 0.1% BSA, 1% penicillin/streptomycin). Infection medium was 
decanted and washed three times with 10 ml DPBS. DPBS was removed from flask 
with a sterile pipette. 5 µl virus stock (PR8 in egg allantoic fluid) was inoculated in 20 
ml infection media to each flask using sterile pipettes including positive and negative 
control. After 1 hr of incubation at 37ºC in 5% CO2 incubator, virus suspension was 
removed and cells were washed once with 10ml DPBS (0.2 % BSA). Afterwards, 30 ml 
of the infection culture media was added to each flask. Cells were checked for clear 
cytopathic effects in the virus-infected flasks (otherwise waited another half day or 
day). When cytopathic effects were observed, the supernatant was collected and 
centrifuged to remove debris. Small aliquots of virus were kept at -80 °C. 
2.2.5. Infection of cells 
For infections where the determination of infectious virus was not required, no trypsin 
was added to the medium. Monolayers of sorted immune cells were infected with virus 
diluted in serum-free DMEM at an appropriate multiplicity of infection (MOI). 
Monolayers were washed prior to infection in PBS to remove all traces of serum. After 
an adsorption period of 1-2 hour on a rocking platform at 37°C, the virus inoculum (or 
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DMEM only for mock infections) was removed and replaced with serum-free DMEM. 
Cells were incubated at 37°C/5% CO2 until harvested. 
2.2.6. In vitro stimulation with death ligands 
Sorted NK cells from the spleen of vavFLIPR mice and WT littermates were stimulated 
with 20 ng/ml CD95L, 20 ng/ml TRAIL, 20 ng/ml TNF-α or PBS for 16 hours. After 
incubation, cells were harvested and analyzed by flow cytometry.  
2.2.7. Cell isolation by flow cytometry 
Primary cells were stained with the respective surface markers and were sorted by 
means of a FACS Aria II or Moflo device and collected in tubes containing PBS. This 
procedure was performed in cooperation with Dr. Lothar Gröbe, head of the flow 
cytometry and cell sorting facility at the Helmholtz Center for Infection Research 
(Braunschweig, Germany). 
2.2.8. Flow cytometry analysis 
For flow cytometry analysis, 1×106 cells were washed in 1 ml PBS at 4 °C, 1500 rpm, 5 
min. Cells were resuspended in 100 µl PBS and stained with LIVE/DEAD for 30 min, 4 
°C in the dark. Thereafter, cells were washed in 1 ml PBS as above. Next, cells were 
resuspended in FACS buffer containing Fc Block antibodies and incubated for 15 
minutes at 4ºC in the dark. Surface markers were stained in 100 µl FACS buffer. Cells 
were incubated with appropriate dilutions of fluorochrome-conjugated or unconjugated 
antibodies at 4 °C for 20 min in the dark. Unbound antibodies were washed away with 1 
ml FACS buffer. For intracellular staining cell were fixed and permeabilised with 
FoxP3 Staining Buffer Set by Miltenyi Biotec (Mönchengladbach, Germany) according 
to supplier’s instructions. 
2.2.9. Mouse infection 
Female animals (12–17 week of age) were anesthetized by intra-peritoneal injection of 
Ketamin-Xylazine solution (10% (v/v) 100 mg/ml ketamine and 5% (v/v) 20 mg/ml 
xylazine in 0.9% (w/v) NaCl) with a dose adjusted to the individual body weight (200 
µl per 20 g body weight) and infected intranasally with the specified dose of virus in 20 
μl sterile PBS. Weight loss and survival of infected mice were monitored over a 14-day 
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period. In addition to mice that were found dead, animals showing more than 20% of 
body weight loss were euthanized and documented as dead. 
2.2.10. Isolation of mouse organ 
Mice were sacrificed by cervical dislocation or CO2. Spleen, peripheral and mediastinal 
lymph nodes were isolated from mice. Organs were homogenized through a 70 µm 
nylon mesh and washed with PBS. Erythrocytes were removed by 2 min incubation in 
ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH adjusted to 7.3 
with NaOH) at room temperature followed by a further washing step. Lungs were 
removed aseptically, and perfused through the right ventricle with 1 mL PBS. Each lung 
was stored in 2ml RNA later buffer (RNA stabilization buffer) in -20 °C until used for 
RNA isolation. 
2.2.11. Histology and immunohistochemistry 
c-FLIPR and WT mice were sacrificed and lung was isolated. Samples were fixed with 
4% formaldehyde and embedded in paraffin. 3µm sections were cut, deparaffinized and 
stained with hematoxilin and eosin for histological analysis. Furthermore, they were 
stained with NP antibody. Histological analysis and immunohistochemistry 
determinations were done in cooperation with Dr. Ulrike Heise and the mousepathology 
facility at the Helmholtz Center for Infection Research (Braunschweig, Germany). 
2.2.12. Determination of cytokines 
Blood was obtained by means of the final heart puncture method. Samples were 
incubated at 37ºC for 1 hour, then 10 minutes at 4ºC and finally centrifuged. The 
supernatant was transferred to another tube and stored at -80ºC. Broncho-alveolar 
lavage (BAL) fluid was collected from an 1 ml PBS instillation and subsequent 
aspiration from the lung of each mouse. Supernatants were aliquoted, stored at -80oC. 
Spleen was isolated from the mice and milled through a 45 µm filter. Cells were diluted 
in 1 ml PBS and centrifuged. The supernatant was transferred to another tube and stored 
at -80ºC. Cytokine levels from serum, spleen and BAL were determined using 
procartaplex mix & match/ mouse 17-plex contains TNF-α, IFN-γ, IFN-α, IL-6, IL-
12p70, IL-17A, IL-10, IL-2, IL-1α, IL-1β, IL-4, IL-21, RANTES, MCP-1, IP-10, MIP-
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1α and MIP-1β in a Luminex® Instrument of the Luminex Corporation (Austin, USA) 
following supplier’s protocol. 
2.2.13. Focus forming assay  
Lungs from infected mice were collected at different time points p.i. and homogenized 
in PBS + 0.1% BSA. Virus titers in these homogenates were determined by FFU assay 
on MDCK (Madin–Darby Canine Kidney) cells. Briefly, 6×104 MDCK cells per well 
were seeded in 96-well culture plates and incubated at 37 °C and 5% CO2 for 24 h. 
Serial 10-fold dilutions of extracts were prepared in MEM containing 2.5 μg/ml NAT 
(N-Acetylated Trypsin, Sigma), 0.1% BSA, 1% penicillin/streptomycin (infection 
medium) and added to MDCK cells. Specific virus stocks (virus in embryonated 
chicken eggs) were used as positive controls for the assay. After 1h of incubation at 37 
°C in 5% CO2, the inoculates were replaced with 100 μl of 1% Avicel overlay prepared 
in DMEM containing 2.5% NAT, 0.1% BSA and the cells were incubated for 24 h. 
Subsequently, the cells were washed twice with PBS and fixed with 4% formalin in 
PBS (100 μl/well) for 10 min at room temperature. Then, the cells were washed twice 
and incubated with Quencher (100 μl/well; 0.5% Triton X-100, 20 mM Glycine in PBS) 
for 10 min at room temperature. Afterwards, the cells were washed with Washing 
Buffer (100 μl/well, 0.5% Tween20 in PBS). The primary antibody (anti-influenza 
Nucleocapsid NP polyclonalgoat antibody, Virostat) and the secondary antibody (anti-
goat-HRP from KPL, MA, USA) were diluted 1:1000 in Blocking Buffer (50 μl/well; 
0.5% Tween, 20% BSA in PBS). 50 μl of the primary antibody was added to each well 
and incubated at room temperature. After 45 min, the cells were washed with Washing 
Buffer, incubated with 50 μl of secondary antibody for 45 min, then washed again and 
incubated with 30 μl of True Blue substrate and exposed until blue spots from infected 
cells appeared (about 30 min). foci were counted under microscopy and viral titers were 
calculated as focus formation units (FFU) per lung 175. 
2.2.14. In vivo NK cell depletion 
In order to deplete NK cells in mice with influenza infection, mice were i.p. injected 
with 50 µL Anti-Asialo-GM1 every 3 days, starting on day before infection. Control 
mice were treated with IgG. After depletion treatments, NK cells in lung and spleen 
were examined by flow cytometry on day 7. 
Material and Methods 
31 
 
2.3. Software   
qPCR and flow cytometry data were analyzed by the Light cycler 96 version 1.1.0.1320 
and FlowJo 10.1r7 respectively. 
 
2.4. Statistical Analysis  
Statistical analyses were performed using Mann-Whitney-tests to determine statistical 
significance, using Graph Pad Prism (Graph-Pad-Software Inc., La Jolla, CA, USA). 
Standard error of the mean (SEM) was represented as error bars in the graphs 
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3. Results 
 
3.1.  Constitutive expression of c-FLIPR does not alter lymphocyte 
populations in vavFLIPR mice in steady state 
Considering the physiological importance of apoptotic responses, it is clear that tight 
regulations of the signaling cascades are needed. The important role of regulatory 
apoptosis signaling molecules has been shown for many years 176. Among several 
regulators of death receptor signaling, c-FLIP has been a matter of interest over the last 
decade 63,177–179. The physiological role of c-FLIPL and c-FLIPS has been well 
characterized in the past few years 70,177,180–182. However, the function of c-FLIPR in the 
immune system is poorly understood. A comprehensive analysis of c-FLIP protein 
expression in cell lines of different species illustrated that only humans express c-
FLIPshort, while other species, even the closely related chimpanzee, express c-FLIPR. 
Therefore c-FLIPR is the only short c-FLIP isoform expressed in mice 
172. A c-FLIPR 
transgenic mouse model (vavFLIPR), was used to further examine the role of murine c-
FLIPR in the immune system. In this mouse model, murine c-FLIPR is under control of 
the vav-promoter and therefore expressed in all hematopoietic compartments. The 
plasmid used for generating the transgenic construct was described by Ogilvy and 
colleagues 174. It was already shown that c-FLIPR expression in vavFLIPR mice was 
comparable to the endogenously expressed c-FLIPR in splenocytes induced by Con 
A173,183. To investigate whether the inhibition of death receptor-induced apoptosis 
results in any alterations in lymphocyte numbers, lymphocyte populations in the spleen, 
lymph nodes and bronchoalveolar lavage of 12-17 week old vavFLIPR mice (n=6) and 
WT littermates (n=6) were analyzed. Both frequencies and total cell numbers of CD3+ T 
cells, CD19+ B cells, NKp46+ NK cells, Ly6G+ neutrophils and F4/80+ macrophages 
were comparable between 12-17 week old littermate WT and vavFLIPR mice (Figure 
10, table 1). Furthermore, the activation status of T cells was analysed in spleen and 
lymph nodes from 12-17 week old WT and vavFLIPR mice by CD44 and CD62L 
staining. No difference in CD44+ antigen-experienced T cells or CD62L+ naïve T cells 
could be observed (Figure 10B). The results indicated that in the steady state condition, 
there is no effect on the lymphocyte populations in vavFLIPR mice compared to WT 
littermates. This is consistent with previous studies where 7 week old vavFLIPR mice 
and WT littermates were analyzed 173. 
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Figure 10. Flow cytometry analyses of CD3+, CD19+, NKp46+, Ly6G+ and F4/80+ cells 
and activation status of CD4+ and CD8+ cells in vavFLIPR and WT littermates. (A) 
Representative dot plots for spleen cellularity in 12-17 week old wildtype ( n=6, upper 
panel) and vavFLIPR mice (n=6, lower panel). Cells from freshly isolated spleens were 
stained for CD3, CD19, NKp46, Ly6G and F4/80. Adult vavFLIPR mice had normal 
numbers of immune cells in the steady state. (B) Representative dot plots of CD44 and 
CD62L cells within the CD4+ and CD8+ compartment from spleen. The frequency of 
CD44+ antigen-experienced T cells and CD62L+ naïve T cells were comparable in 
vavFLIPR mice and WT littermates. 
 
 
 
(A) 
 
(B) 
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Mouse 
strain 
Organ 
Percentage of all acquired cells 
Absolute 
numbers 
x 1.0E+07 CD3 CD4 CD8 CD19 NKp46 
WT Spleen 20.6 (±4.7) 10.3 (±2.7) 8.20 (±1.0) 23.4 (±6.7) 0.92 (±0.5) 6.7 (±1.4) 
vavFLIPR Spleen 21.7 (±3.5) 11.6 (±2.3) 7.45 (±1.5) 22.7 (±6.4) 0.87 (±0.3) 6.3 (±2.3) 
WT 
Lymph 
node 
33.9 (±3.7) 23.8 (±2.5) 16.0 (±2.2) 10.5 (±1.1) 0.21 (±0.03) 1.6 (±0.6) 
vavFLIPR 
Lymph 
node 
34.1 (±2.9) 22.1 (±2.0) 17.7 (±1.0) 12.1 (±1.6) 0.19 (±0.04) 1.4 (±1.3) 
 
Table 1. Percentage and absolute cell number of CD3+, CD19+, NKp46+, Ly6G+ and 
F4/80+ cells in vavFLIPR mice and WT littermates. (Standard deviation). 
 
3.2. vavFLIPR mice are more susceptible to influenza virus infection 
Death receptor-mediated apoptosis is a key mechanism for the control of immune 
responses and dysregulation of this pathway is associated with many pathogenic 
conditions and may even be central in the pathogenesis of many diseases 176. The death 
receptor-mediated signaling pathway has been shown to be closely related to the 
pathology of IAV infection 184–186. Abnormally elevated expression of death ligands has 
been found in lethal IAV infections. Aberrant induction of apoptosis caused by death 
ligands is related to multi organ disorders, which occur in severe IAV infections 187. 
Apoptosis is also known as a major mechanism of elimination of activated T cells 
during an immune response to viral infection 188.  
It has been demonstrated that c-FLIPS is crucial during the early phase of an immune 
response in humans 180. To study whether expression of c-FLIPR modulates the immune 
response during viral infection, vavFLIPR mice were challenged with IAV. Influenza 
was chosen since it is still not well known how apoptosis signaling affects IAV 
infection and replication. vavFLIPR and WT female mice in the age of 12-17 week were 
intranasally infected with 2x103 FFU PR8 (H1N1) virus. Control mice were given an 
equal volume of PBS for mock infection. Body weight and sickness score of mice were 
recorded daily over a period of 14 days post infection (Figure 11). As illustrated in 
Figure 11, in the early phase of infection, weight loss curves in vavFLIPR and WT mice 
were similar. However, vavFLIPR mice showed slightly higher body weight loss 
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compared to WT mice at the peak of infection. Notably, 100% of the WT, as well as 
vavFLIPR mice, were able to recover and regain body weight. 
 
Figure 11.  Morbidity and weight loss comparison during influenza A virus infection. 
vavFLIPR and WT female mice at the age of 12-17 week were infected 
intranasally with 2x103 FFU PR8 (H1N1) influenza A virus. Following infection, mice 
were checked daily for weight loss. (A) The weight of vavFLIPR mice (Red) was a bit 
lower than the WT littermates (black) at the peak of infection. Mock infected animals 
from WT and vavFLIPR mice did not lose weight or showed signs of disease. Data are 
presented as mean value +/- SEM. (B) Mice were evaluated daily and scored for 
individual symptoms. Ruffled fur (absent = 0; present = 1), hunched back (absent = 0; 
present = 1) and activity (normal = 0; reduced = 1; severely reduced = 2) were 
evaluated. The final score was the addition of each individual symptom score. The 
minimum score was 0 for the control mice and 1-4 for the IAV infected mice, 
depending on the severity. 
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3.3. vavFLIPR mice have a higher viral load compared to WT mice at the 
peak of infection 
To investigate whether the high susceptibility of vavFLIPR mice is partially due to 
enhancing viral replication and associated tissue damage or a detrimental 
immunopathology of the host response, or both, viral load was analyzed by determining 
mRNA copies of the (NP) gene in the lung. In the early phase of infection (day 1-2 post 
infection), the number of NP copies was comparable between littermate WT and 
vavFLIPR infected mice. However, the virus replicated to a significantly higher titer in 
vavFLIPR mice compared to WT mice at the peak of infection.  This was additionally 
confirmed by foci assays indicating replication-competent virus (Figure 12B). Notably, 
the virus titers in vavFLIPR mice, as well as WT mice, were below the level of detection 
at day 10 post infection. 
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Figure 12. (A) Viral load kinetics in the lungs of the vavFLIPR mice and WT 
littermates. After intranasal infection of female mice at the age of 12-17 week with 
2x103 FFU PR8. Influenza virus titers were evaluated in lung supernatants of WT (white 
bars) and vavFLIPR (black bars) mice by qPCR with at least two technical replicates for 
each sample. vavFLIPR mice had a higher virus titer in the lungs. Bar graphs represent 
the mean; error bars represent SEM. Statistical analyses were performed using two-
tailed Mann-Whitney tests; (*) indicate p < 0.05. (B) Viral load in the lungs of influenza 
infected vavFLIPR (n=5) and WT (n=5) mice were measured on day 7 p.i. by focus formation 
assay indicating replication-competent virus. foci assay recapitulated the qPCR results. 
vavFLIPR mice had a higher viral titer in the lungs. foci assay was performed with three 
technical replicates for each sample. Statistical analyses were performed using two-
tailed Mann-Whitney tests; (*) indicates p < 0.05. 
 
 
Results 
38 
 
3.4.  Histological analysis confirmed the observed higher viral load in 
vavFLIPR mice 
To verify the results of the qPCR analysis, a histological study was performed. 
Histological sections of the lungs from influenza infected vavFLIPR and WT mice, were 
examined on day 7 post infection. Large patches of virus-infected cells (brown staining) 
were detected in vavFLIPR mice compared to WT mice. This data recapitulated the 
qPCR data which showed a higher viral titer in vavFLIPR mice at the peak of infection. 
All infections were performed at an infection dose of 2×103 FFU. Control mice were 
given an equal volume of PBS for mock infection. 
 
 
Figure 13. Histological sections of lungs of WT and vavFLIPR mice infected with the 
PR8 virus. Mice were infected intranasally with 2×103 FFU of H1N1 virus. Control 
mice were given an equal volume of PBS for mock infection. 7 days post infection, lung 
sections were stained with hematoxilin and eosin for histological analysis. Furthermore, 
they were stained with anti-influenza NP antibody. PR8 infected cells were observed in 
the lungs of the vavFLIPR and WT littermates (Red dots). Large patches of virus-
infected cells were detected in vavFLIPR mice compared to WT mice. 
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3.5. Immune cell composition in vavFLIPR and WT littermates following 
IAV infection 
In response to influenza A infection, the host develops a complicated antiviral response 
to fight against the virus. Both the innate and adaptive immune system participate in the 
containment and clearance of viral infection, which takes place in about a week 189. For 
a long time, apoptosis was regarded mainly as a host cell defense mechanism, as many 
viruses express antiapoptotic proteins to prevent this cellular response. It has been 
shown that three of the 11 viral gene products, namely NS1, PB1 and M2 ion channel, 
were implicated in the manipulation of programmed cell death 190,191. More recent data 
illustrated, however, that viruses can also take advantage of proapoptotic signaling 
events to increase the efficiency of their replication machinery within the apoptotic cell 
185. Furthermore, apoptosis induced by extracellular death signals is now regarded as a 
crucial event that occurs regularly during innate and adaptive immune responses toward 
several kinds of pathogens, including IAV. To understand whether the observed 
differences in the host suseptibility, following influenza infection, are due to innate or 
adaptive immunity, vavFLIPR and WT female mice at the age of 12-17 week were 
intranasally infected with 2x103 FFU of PR8 (H1N1) virus. The composition of immune 
cells was analyzed in influenza infected vavFLIPR and WT littermates on day 7 post 
infection. Flow cytometry data from spleen (Figure 14A) and the mediastinal lymph 
node (Figure 14B) indicated that both, frequencies and total cell numbers of CD19+ B 
cells, CD3+ T cells as well as the CD4+ helper T cell and CD8+ cytotoxic T cell subsets 
were comparable between infected vavFLIPR mice and the WT littermates. 
Furthermore, the activation status of T cells was analysed in spleen and mediastinal 
lymphnodes from 12-17 week old infected WT and vavFLIPR mice by CD44 and 
CD62L staining on day 7 post infection. No difference in CD44+ antigen-experienced T 
cells or CD62L+ naïve T cells could be observed. 
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Figure 14. Freshly isolated splenocytes and lung draining lymph node cells (DLN) from 
WT (n=6) and vavFLIPR (n=6) mice were stained with antibodies directed against CD3, 
CD4, CD8 and CD19 followed by FACS analysis. Individual mice are shown as 
separate symbols. Horizontal lines represent the mean of frequencies from three 
independent experiments; error bars display s.e.m. CD3+ T cells, CD19+ B cells, CD4+ 
T helper cells within the CD3+ compartment and CD8+ cytotoxic T cells within the 
CD3+ subset in spleen (A) and mediastinal lymph node (B). 
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3.6. IAV infected vavFLIPR mice have a higher number of NK cells 
compared to WT littermates 
Natural killer cells are a population of innate lymphoid cells, which exhibits potent 
cytotoxic activity and cytokine production 192. NK cells also have a role in the 
regulation of the adaptive immune response, and have been shown, in different contexts, 
to stimulate or inhibit T cell responses 193. In many virus infections, natural killer cells 
are critical for the rapid containment of virus replication  194–196 . However, the exact 
role of NK cells in IAV infection is still a matter of debate 197,198. In this study, upon 
IAV infection, the frequency and total NK cell number in vavFLIPR mice and WT 
littermates were analyzed, using NKp46 flow cytometry antibody. The lymphocytes 
were live gated during acquisition using the side and forward scatter dot plot display. 
Furthermore, by using the negative gating strategy, CD3- and CD19- lymphocyte 
populations were identified. The NK cell population was further identified by NKp46+ 
cells (Figure 15). Interestingly, Flow cytometry analysis illustrated that, at the peak of 
infection, the frequency and total numbers of NK cells were higher in the spleen (Figure 
16A). Similarly, the percentages and absolute numbers of NK cells were higher in the 
mediastinal lymph node (Figure 16 B) and bronchoalveolar lavage fluid (Figure 16C) of 
vavFLIPR mice compared to WT littermates.  
 
Figure 15. Flow cytometry gating and identification strategy for NK cells. Mice were 
intranasally infected with PR8 influenza. On day seven post-infection, mediastinal 
lymph node NK cells were examined for NKp46 marker by flow cytometry. 
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Figure 16. vavFLIPR mice had a higher number of NK cells at the peak of IAV 
infection. Single cell suspensions from spleen (A) and the mediastinal lymph node (B) 
and bronchoalveolar lavage (C) of infected vavFLIPR (black) and WT (white) mice 
stained with the NKp46 marker. NK cell frequencies and cell numbers were determined. 
Representative dot plots are shown in (A-C). Horizontal lines represent the mean of 
frequencies from three independent experiments; error bars display SEM. Statistical 
analyses were performed with two-tailed nonparametric Mann Whitney U tests. 
*p<0.05, ***p<0.001. WT (n=6), vavFLIPR (n=7) 
 
Next, to compare NK cell apoptosis in IAV infected vavFLIPR and WT mice, Sorted 
NKp46+ cells, CD4+ and CD8+ T cells from infected vavFLIPR and WT mice were 
stained with active caspase 3/7 stain for 10 minutes and analyzed with flow cytometry. 
The result indicated that the frequency of active caspase 3/7 in CD4 and CD8 cells were 
comparable in IAV infected vavFLIPR and WT mice. However, vavFLIPR mice have a 
lower frequency of active caspase 3/7 in NK cells (Figure 17). 
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Figure 17. (A) Representative flow cytometry histogram of active caspase 3/7 in 
NKp46+, CD8+ and CD4+ cells in vavFLIPR and WT mice on day 7 post infection. (B-C) 
Summary graph of frequencies of active caspase 3/7 in NKp46+, CD8+ and CD4+ cells in 
bronchoalveolar lavage. Active caspase 3/7 is comparable in CD8+ and CD4+ cells. 
However, NKp46+ cells in vavFLIPR mice showed significantly lower active caspase 
3/7. Active caspase 3/7 is displayed as the mean ± SEM. from three independent 
experiments. Statistical analyses were performed with two-tailed nonparametric Mann 
Whitney U tests. *p<0.05, ***p<0.001. 
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3.7. Kinetics of NK cell accumulation does not alter in vavFLIPR mice 
Prior studies examinied the contribution of NK cells to IAV immunity have shown 
disparate results 195,197,199,200. Therefore, to determine if the kinetics and location of NK 
cells during IAV infection are altered in vavFLIPR mice, vavFLIPR mice and WT 
littermates were infected with 2x103 FFU PR8 (H1N1) influenza A virus and then NK 
cell numbers were quantified in the lung draining lymph node (DLN) and spleen by 
flow cytometry. Following infection, both groups of mice showed similar kinetics till 
day 10 post infection.  Notably, on days 7 and 10 post infection, the numbers of NK 
cells were higher in vavFLIPR mice compared to WT littermates (Figure 18). 
 
Figure 18. Kinetics of NK cell accumulation during IAV infections. vavFLIPR (n=6) 
and WT (n=6) mice were infected with IAV infection. NK cells were enumerated in the 
lung draining lymph node (DLN) and spleen at the indicated time points by flow 
cytometry. Shown are NKp46+ cells. Statistical analyses were performed using two-
tailed Mann-Whitney tests; *p<0.05, ***p<0.001. 
 
3.8. vavFLIPR mice have a higher level of proinflammatory cytokines 
compared to WT mice at the peak of infection 
Following influenza infection, activated immune cells produce different cytokines and 
chemokines 201. Cytokines such as TNF-α and IFN-γ have important roles in 
coordinating the antiviral immune response and can also have direct antiviral effects. 
Although TNF-α was first noted for its role in the killing of tumor cells 202, it has 
pleiotropic functions that include the inflammatory response and host resistance to 
pathogens 203,204. IFN-γ is primarily produced by T cells and NK cells and its function is 
to activate macrophages. It has been shown that IFN γ treatment at the early stages of 
influenza virus infection protects mice from death in a NK cell-dependent manner 205. 
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However, excessive inflammation due to the overabundant production of 
proinflammatory cytokines and chemokines has been shown as one of the main factors 
in disease pathogenesis 82,123,206.  Because both apoptosis and the pro-inflammatory 
response have a definitive role in the pathogenesis of influenza virus, to assess the 
contribution of the proinflammatory cytokine responses in the severity of influenza 
infection in vavFLIPR mice, cytokine protein levels in bronchoalveolar lavage, spleen 
and serum were assessed by Bio-plex cytokine assay and the Luminex® instrument. 
Compared with the infected WT mice, infected vavFLIPR mice had a higher level of 
IFN-γ and TNF-α in bronchoalveolar lavage (Figure 19A), spleen (Figure 19B) and 
serum (Figure 19C) on day 7 post infection.  
In addition to cytokines, multiple chemotactic molecules are induced following 
influenza virus infection. In fact, the production of several chemokines, both locally and 
systemically, correlate with influenza virus pathogenesis 207–209. Chemokines and their 
receptors play an important role in site-directed migration and activation of immune 
cells. Elevated levels of MCP-1 (CCL2) and IP-10 (CXCL10) were reported in the 
serum of patients infected with H5N1compared to patient infected with H1N1 210. 
Moreover, elevated levels of RANTES (CCL5) mRNA were detected in human primary 
macrophages following infection with H5N1 as compared to H1N1 or H3N2 infection 
211. To examine the contribution of the chemokine production in the severity of 
influenza infection in vavFLIPR mice, chemokine protein levels in bronchoalveolar 
lavage, spleen and serum were assessed by Bio-plex cytokine assay and the Luminex® 
instrument. Infected vavFLIPR mice had higher levels of MIP-1α and RANTES in 
bronchoalveolar lavage (Figure 20A), spleen (Figure 20B) and serum (Figure 20C) on 
day 7 post infection. Furthermore, the concentration of  IFN-α, IL-6, IL-12p70, IL-17A, 
IL-10, IL-2, IL-1α, IL-1β, IL-4, IL-21, MCP-1, IP-10, MIP-1β were analyzed on 
different time points ( day 0, 1, 2, 3, 5, 7, 10, 14 p.i.). However, no differences could be 
identified between WT and vavFLIPR mice. 
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Figure 19. Comparison of proinflamatory cytokines in vavFLIPR and WT littermates at 
the peak of IAV infection. Concentration of IFN-γ and TNF-α were determined in the 
bronchoalveolar lavage (A), spleen (B) and serum (C) of IAV infected vavFLIPR 
(black) and WT (white) mice on day 7 post infection, by Luminex® assay (n=4 each). 
Bar graphs represent the mean; error bars represent SEM. Statistical analyses were 
performed using two-tailed Mann-Whitney tests; *p<0.05, ***p<0.001. Higher levels of 
the IFN-γ and TNF-α were detected in vavFLIPR mice. 
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Figure 20. Chemokine concentrations in the vavFLIPR and WT littermates at the peak 
of IAV infection. Concentrations of RANTES and MIP1-α were determined in the 
bronchoalveolar lavage (A), spleen (B) and serum (C) of IAV infected vavFLIPR 
(black) and WT (white) mice on day 7 post infection, by luminex assay (n=4 each). Bar 
graphs represent the mean; error bars represent SEM. Statistical analyses were 
performed using two-tailed Mann-Whitney tests; *p<0.05, ***p<0.001. Higher level of 
MIP-1α was detected in vavFLIPR mice. 
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3.9. Degranulation is impaired in NK cells of vavFLIPR mice during 
influenza infection 
In order to functionally characterize NK cells of the vavFLIPR mice, NK cells from 
vavFLIPR and WT mice were isolated from spleen. A standard cytotoxicity assay with 
YAC-1 target cells was employed to assess NK cytotoxicity. The result indicated that 
the cytotoxicity of NK cells in vavFLIPR and WT mice were comparable (Figure 21). In 
addition, to further assess FLIPR-related changes in NK cell function, degranulation was 
measured with the CD107a assay. CD107a is localized to lysosomes and cytolytic 
granules in resting NK cells 212,213. Upon activation, NK cells degranulate their cytolytic 
contents and CD107a appears on the NK cell surface. First, the degranulation response 
of wildtype and vavFLIPR NK cells upon co-culturing with YAC-1 target cells was 
analyzed. Cell-surface exposure of CD107a was determined by flow cytometry. In order 
to compare degranulation of natural killer cells following interaction with influenza-
infected cells, the expression level of CD107a was analyzed in vavFLIPR mice and WT 
littermates during the course of IAV infection. Percentages of the CD107a+ NK cells 
were similar in uninfected mice however, CD107a+ were significantly lower in the NK 
cells of the infected vavFLIPR mice compared to WT littermates (Figure 22). 
(A)                                                                (B) 
 
 
Figure 21. cFLIPR did not change the ability of NK cells to kill YAC-1 cells. NK cells 
of healthy (A) and IAV infected (B) vavFLIPR and WT littermates were incubated with 
YAC1 cells at the ratio of 1:8 for 16 hr. After the incubation time, cells were harvested 
and analyzed with flow cytometry. 
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Figure 22. NK cell degranulation during influenza infection is impaired in vavFLIPR 
mice. NK cells from spleens of the uninfected and infected vavFLIPR and WT 
littermates were incubated with YAC-1 cells at an effector to target ratio of 1:1 in the 
presence of brefeldin A, monensin and BV-CD107a antibody for 2 hours. Surface 
expression of CD107a on the uninfected and infected NK cells of vavFLIPR mice and 
WT littermates were tested by FACS analysis using anti-CD107a antibody. The 
percentage of NK cells positive for CD107a were significantly lower in infected 
vavFLIPR mice compared to WT littermates. Statistical analyses were performed using 
two-tailed Mann-Whitney tests; *p<0.05. 
 
3.10. Higher number of NK cells contribute to the severity of the influenza 
infection in vavFLIPR mice 
Early studies showed that NK cells within the lung have a higher cytolytic activity 
following IAV infection and are important for survival, as their depletion from hamsters 
or mice with Anti-Asialo-GM1 antibody resulted in increased morbidity and mortality 
compared to undepleted controls 194,214. Conversely, more recent studies have observed 
that NK cells contribute to the immunopathology in influenza infection 215,197. To 
investigate the influence of a higher number of NK cells on the host outcome during 
influenza infection, mice were treated with Anti-Asialo-GM1 to deplete NK cells in 
vivo prior to and during influenza infection. Anti-Asialo-GM1 was reported effective at 
depletion of NK cells in vivo 216,217, as confirmed by our flow cytometric analysis of 
vavFLIPR and WT mice spleen (Figure 23A). Body weight of the NK cell depleted 
vavFLIPR and WT mice were recorded daily over a period of 14 days post infection 
(Figure 23B). As illustrated in Figure 23, weight loss curves in NK cell depleted-
vavFLIPR and NK cell depleted-WT mice were similar and no significant difference 
could be observed in body weight loss/gain. 
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(A) 
 
 
 
 
 
 
(B) 
 
Figure 23. In vivo NK cells depletion with Anti-Asialo-GM1. Mice were inoculated i.p. 
with 20 µg Anti-Asialo-GM1 antiserum (or IgG control), 1 day prior to infection and 
received another 20 µg on day 2 and 5 p.i. The efficiency of depletion is shown in (A). 
(B) Following infection, mice were monitored daily for body weight. Both Anti-Asialo 
treated groups (vavFLIPR and WT) were more susceptible to influenza infection 
compared to controls. Notably in the absence of NK cells, the slight difference which 
was observed between infected vavFLIPR and WT mice disappeared. Data are presented 
as mean value +/- SEM. n= 5 per group of mice.  
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3.11.  Improved outcomes for influenza-infected vavFLIPR mice by 
depletion of NK cells 
Previous studies showed that different inbred mouse strains exhibit large differences in 
their response to 2x103 PFU PR8 infection 218. To determine whether NK cells played a 
role in higher viral load at the peak of infection, NK cells were depleted using Anti-
Asialo-GM1 antibody. Mice depleted of NK cell were infected with 2x103 FFU 
influenza virus and the viral load was measured on day 7 post infection with qPCR and 
foci assay. NK cell depletion resulted in a higher viral load in vavFLIPR and WT mice 
compared to IgG controls. Notably, although the viral load is higher the differences in 
vavFLIPR and WT mice disappeared, which suggested that an excessive number of NK 
cells are involved in higher viral load in vavFLIPR mice at the peak of infection. 
 
Figure 24. qPCR and foci assay analyses of the lungs of vavFLIPR and WT littermates. 
NK cell-depleted and control mice were infected with influenza virus. Virus titers 
determined by qPCR (A) and foci assay (B) on day 7 post-infection. In the absence of 
NK cells, vavFLIPR and wild type mice showed a similar viral load. Bar graphs 
represent the mean; error bars represent SEM. Statistical analyses were performed using 
two-tailed Mann-Whitney tests; *p<0.05, ***p<0.001. 
 
3.12. Influenza virus can directly infect primary mouse NK cells 
 NK cells face influenza viruses within the microenvironment of infected cells, and are 
important for the host innate immunity during influenza virus infection. NK cells can 
recognize and kill influenza virus-infected cells 219,220. To counteract this killing, 
however, influenza virus has developed an escape strategy that inhibits NK cell 
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cytotoxicity by increasing the binding of two inhibitory receptors to the infected cells 
after infection 221.  It is, therefore, important to investigate the direct effects of influenza 
virus on NK cells. First, it was studied whether influenza virus could directly infect NK 
cells. Freshly isolated primary NK cells were infected with H1N1 and subsequently 
washed and cultured. Using RT-PCR, the NP gene was detected in influenza virus-
exposed NK cells but not in mock-treated NK cells. In parallel, purified resting primary 
mouse CD4 T cells, which cannot be directly infected by the influenza virus 222 were 
included as a negative control. No NP gene was detected in influenza virus-exposed 
CD4 T cells. After 6 hrs the supernatants from infected NK cells were collected and 
inoculated onto MDCK cells to determine if infectious progeny were produced. The 
results illustrated that influenza virus could replicate in primary NK cells. 
 
 
(A)           (B) 
Figure 25. Influenza virus directly infects primary murine NK cells. (A) NK cells from 
vavFLIPR mice and WT littermates were incubated with influenza virus H1N1 at a 
multiplicity of infection (MOI) of 2. After 1 hr of viral adsorption, unadsorbed viruses 
were washed away by excess phosphate buffered saline. CD4 cells were treated in 
parallel as a negative control. The expression of viral NP mRNA was detected by q-
PCR in influenza virus-exposed NK cells but not in CD4 treated cells. (B) Additionally, 
the supernatants from infected NK cells were collected and inoculated onto MDCK cells 
to determine whether infectious progeny were produced and since infectious particles 
were detected, it was concluded that Influenza virus can replicate in primary NK cells.  
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3.13. NK cell depletion results in significantly more CD4 T cells in the lung 
during IAV Infection 
It has been shown that NK cells can kill activated CD4 T cells during lymphocytic 
choriomeningitis virus (LCMV) infection 223. To determine whether NK cells similarly 
reduce the number of CD4 and CD8 T cells during IAV infections, CD4 and CD8 T 
cells were quantified in NK-depleted and non-depleted mice. The number of CD8 T 
cells in the lung did not differ significantly between non-depleted and NK-depleted 
mice. However, there was a significant increase in the total number of CD4 T cells in 
the lungs of NK-depleted mice at day 7 p.i. 
 
Figure 26. NK cell depletion results in significantly more CD4 T cells in the IAV 
infected lung. vavFLIPR and WT mice were depleted of NK cells or treated with IgG, 1 
day prior to infection and received another 20 µg on day 2 and 5 p.i.  (A) On day 7 post 
infection the number of CD4 and CD8 T cells in NK-depleted and non-depleted mice 
was enumerated by flow cytometry. The number of CD8 T cells in the lung did not alter 
in the NK-depleted mice compared to non-depleted mice. However, there was a 
significant increase in the total number of CD4 T cells in the lungs of NK-depleted mice 
at day 7 p.i. Bar graphs represent the mean; error bars represent SEM. Statistical 
analyses were performed using two-tailed Mann-Whitney tests; *p<0.05, ***p<0.001. 
n.s., not significant. Data were pooled from 2 independent experiments with a total of 4 
mice per group 
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4. Discussion 
 
4.1. Investigation of the role of c-FLIP in anti-viral immunity 
Programmed cell death is a complex physiological cellular process that maintains 
homeostasis and plays an important role in the protection of multicellular organisms 
from diseases 224,225. Apoptosis is the most prominent type of programmed cell death 224. 
Apoptosis can be triggered by extrinsic signals, such as the binding of ligands to cell 
surface death receptors 34. Deregulation of the apoptosis machinery has been found in 
different diseases 224. Apoptosis has been often described as a mechanism of host 
defense, which can eliminate infected cells, reduce the spread of infection to 
neighboring cells and prevent pathogen persistence 226,227. Different viruses have been 
shown to induce apoptosis in the host such as human cytomegalovirus, duck swollen 
head hemorrhagic disease virus and influenza A virus. 228–231. In this respect, it has been 
demonstrated that influenza virus infection increases the expressions of both Fas and 
FasL on HeLa cells. Ligation of Fas/FasL on the surface of virus-infected cells mediates 
apoptosis 232–234. Anti-Fas or FasL antibodies have been reported to partially suppress 
virus-induced apoptosis 235. Notably, apoptosis has to be tightly regulated since too little 
or too much cell death may lead to pathology 14,240. During the past few years many 
efforts have been made to study the molecular mechanisms of the apoptosis signaling 
pathway and its regulatory systems 74,237,238. The anti-apoptotic c-FLIP proteins inhibit 
apoptosis in the extrinsic pathway by preventing initiator caspase-activation at the 
signaling complex of death receptors  239,240. Although the physiological role of c-FLIPL 
and c-FLIPS is well characterized, the function of c-FLIPR in the immune system is 
poorly understood. In 2013 Telieps et al., could show that adult vavFLIPR mice, which 
constitutively express murine c-FLIPR in all hematopoietic cells, have normal numbers 
of immune cells in the steady state 173. However, when challenged with Listeria 
monocytogenes, vavFLIPR mice exhibited better bacterial clearance, less liver necrosis 
and less caspase 3 activation compared with infected WT littermate. Thus, it was 
concluded that early apoptosis occurring during Listeria monocytogenes infection is 
restricting bacterial clearance and c-FLIPR expression in hematopoietic cells supports an 
efficient immune response against bacterial infections. Unexpectedly, in this work, 
challenging vavFLIPR mice with IAV infection resulted in a different outcome 
compared to bacterial infection. vavFLIPR mice were more susceptible to influenza 
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infection than WT mice, showing slightly increased weight loss at the peak of the 
infection. Additionally, vavFLIPR mice had a significantly higher viral load compared 
to WT mice at the peak of infection. Firstly, while some minor increases in viral titers 
were observed within the first 3 days following influenza virus infection, huge 
differences in viral titers were seen on day 5 and day 7 post infection. This data suggests 
that preventing apoptosis of the immune cells during influenza infections is in favor of 
influenza virus replication and does not have a beneficial effect on viral control. 
Notably, both vavFLIPR and WT mice could clear the virus by day 10 post infection and 
viral titers were below the level of detection on day 10 post infection. It is likely that a 
stronger adaptive immune response in vavFLIPR mice could control the viral replication 
after day 7 post infection. 
 
4.2. Following influenza A infection, vavFLIPR mice have a higher 
number of NK cells 
Upon influenza infection, the host develops innate and adaptive immune response, 
which aim at clearing the infection. CD8+ and NK cells contribute mainly in elimination 
of influenza virus infected cells during influenza infection 148,214,215,241,242. Upon 
influenza virus infection, CD8+ cells are activated in the lymphoid tissue and recruited 
to the site of infection. CD8+ T cell effector functions involve the ability to produce a 
variety of cytotoxic molecules such as perforin and granzymes, as well as the 
secretion of a variety of cytokines such as TNF-α and IFN-γ 148. Clearance of the IAV 
infection in perforin deficient mice was impaired 148. This indicates that perforin-
dependent cytotoxicity plays a critical role in limiting IAV infection.  Intrestingly, mice 
deficient in both granzyme A and B could effectively control infuenza A virus infection 
243. It is likely that other cell death pathways or other granzymes compensate for the 
absence of granzyme A and B and contribute to the control of the IAV infection. A 
more recent study uncovered that CD8+ T cells can also utilize TRAIL to kill virally-
infected cells 244.  
In the context of this thesis, no significant difference was observed in the frequency or 
the total number of CD8+ T cells between infected vavFLIPR and WT mice. 
Interestingly, frequencies and total cell numbers of the NK cells were significantly 
higher in the mediastinal lymph node, spleen and bronchoalveolar lavage of infected 
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vavFLIPR compared to WT mice. NK cells mediate host immune responses to viral 
infections through two main effector functions, natural cytotoxicity and cytokine 
production 245. During the innate immune response against influenza infection, NK cells 
get activated, produce IFN-γ and fulfill cytotoxic reactions. The critical role of NK cell 
in influenza virus infection was further illustrated by a study, which showed that NK 
cells can kill influenza infected cells in vitro by the engagement of viral hemagglutinin 
with the NKp46 receptor on NK cells 246. Recently it has been demonstrated that in 
response to influenza virus infection, conventional NK cells produce IL-22, which is 
epithelial regenerative and inflammation protective 247. NK cells can also directly or 
indirectly affect the phenotype of numerous cell types, which play a role in immunity 
248–250.  It has been documented that NK cells can increase DC and CD8 T cell migration 
to the DLN during IAV infection. However, the frequency and cell number of DCs were 
also comparable between influenza infected vavFLIPR and WT mice. The results of this 
thesis show that NK cells are actively recruited to the lung-draining LN during IAV 
infection. The higher frequency of NK cells in lung-draining LN was seen even on day 
10 post infection. Although there were no statistical differences in the number of CD8 
or DC in vavFLIPR mice, it is possible that a higher number of NK cells affected CD8 
or DC cell function, which remains to be determined. Since the higher number of NK 
cells was the only difference that was founded between the vavFLIPR and WT mice, it 
was hypothesized that NK cells might contribute to the severity of influenza infection in 
vavFLIPR mice. 
 
4.3. NK cells exacerbate the pathology of influenza virus infection in mice 
The exact role of NK cells in the immune response against different virus families, 
including the orthomyxovirus is intricate. Shortly after viral infection, NK cells are 
recruited to the infection area, become activated and subsequently secret cytokines 251.  
A critical role of NK cells in the development of the adaptive immune response against 
influenza virus infection has been demonstrated 196,249,252,253. Several studies have 
pointed out the importance of NK cells in the control of IAV infection, in which 
depletion of NK cell or defect in NK cell activity can cause morbidity and mortality or 
delayed in viral clearance 214,215 . However, there were some examples, which illustrated 
that NK cells exacerbate pathology during influenza virus infection in mice 197–199. 
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These discrepancy between the results raise the interesting possibility that NK cells 
might have beneficial or deleterious function during influenza virus infection. Host 
genetic background, viral strain and infection viral dose are three important factors, 
which can be determinative. It has been demonstrated that different host genetic 
backgrounds result in different resistance to IAV infection and depletion of NK cells 
can result in totally different outcomes 
 depending on the host background  199,254. Considering the infection dose, it has been 
reported that depletion of NK cells ameliorates the survival rate in high, but not medium 
or low-dose influenza infection 197. Similarly, in another study, it has been shown that 
virus dosage can affect the immunoregulatory function of NK cells 223.  
In this thesis NK cell depletion in vavFLIPR and WT mice resulted in an increase in 
viral load at the peak of infection compared to control mice (Figure 24). However, in 
the absence of NK cells, the viral load differences between vavFLIPR and WT mice 
disappeared. All together it was concluded that the higher number of NK cell was an 
unfavorable factor for the host in vavFLIPR mice. Comparing the kinetic of NK cells in 
high and low dose of influenza infections might be helpful in better understanding the 
two-sided role of NK cells in immunity during IAV infections. 
 
4.4. IAV virus can infect and replicate in primary mouse NK cells  
NK cells are considered as first line of defense against influenza A infection because 
they are able to act before T cell and B cell activation can happen. Being part of the 
host’s innate immunity, NK cells can rapidly exterminate virus-infected cells, which 
limits viral replication and transmission. Viruses and NK cells are in constant combat. 
In response to NK cells activity, viruses develop different types of strategies to evade 
them 255,256. In the case of Influenza, the virus increases its rate of replication during the 
acute phase of infection. Rapid viral synthesis provides enough time for the influenza 
virus to establish a stable virus titer 257. A high number of virus particles overwhelms 
the limited number of surrounding NK cells 205,258. The interaction of NKp46 with 
influenza HA is an important control strategy for NK cells to kill influenza-infected cell. 
However, Influenza can also modify its main surface proteins HA and NA frequently, in 
order to avoid antibody neutralization259 . Moreover, the influenza virus stabilizes 
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MHC-I expression in infected cells, and therefore initiate signals that inhibit NK 
activation 221,257,260. Additionally, there have been reports that the influenza A virus NS1 
protein can inhibit apoptosis in infected cells 190,261,262. However, other studies have 
concluded that the virus enhances apoptosis 185. In this respect, it has been demonstrated 
that in the presence of an inhibitor that blocks caspase 3, influenza virus propagation 
was impaired 185. It was concluded that apoptosis induction, specifically activation of 
caspase 3, is required for efficient influenza virus propagation. 
In this thesis, it has been shown that influenza virus could directly infect and replicate in 
primary mouse NK cells. Direct viral infection of NK cells has been demonstrated for 
herpes simplex virus, Epstein-Barr virus, human immunodeficiency virus and 
ectromelia virus 263–266. Among innate immune cells, influenza direct infection was first 
reported in macrophages 211,267,268. Infection and killing the immune cells, including NK 
cells comprise a potential immune-evasive action.  
In this study, using foci assay and qPCR, we demonstrated that NK cells are susceptible 
to influenza virus. Notably, using the same MOI for infection indicated that efficiency 
of influenza virus infection of NK cells is lower than MDCK cells. Virus replication in 
infected cell can be either productive or abortive. In this study, as evidenced by positive 
foci assay result, replication was productive.  
 
4.5. Decreased cytotoxicity in vavFLIPR NK cells 
NK cells from influenza infected vavFLIPR mice showed a significant reduction of their 
cytotoxicity against YAC-1 cells. As a response to influenza virus infection, virus-
infected respiratory epithelial cells release inflammatory chemokines that recruit NK 
cells to the site of infection 192. NK cells combat influenza infection by destroying the 
infected cells, which results in the release of viral particles that can be neutralized by 
antibodies. Upon NK cell stimulation, the activation signal mediates a downstream 
cascade of kinase activation, which results in exocytosis of cytotoxic granules and 
subsequently kills the target cells 135,269,270. The balance between the inhibitory and 
activating receptors control the cytotoxicity of NK cells 269. Following influenza 
infection, recognition of the missing self signal or the increased activating signals can 
advocate  NK cells 271. On the other hand, influenza virus develops evasion strategies, 
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which can enable the virus to impair the effector functions of NK cells. As a part of 
immune evasion strategies, the virus can directly infect NK cells and induces cell 
apoptosis 272. Direct infection of NK cells by influenza virus can interfere with the 
ability of NK cells to effectively recognize and kill the host cells. It has been reported 
that influenza infected NK cells have less cytotoxicity against EL4H60 cells compared to 
the mock-infected NK cells. EL4H60 is a cell line which expresses H60, which is a 
known ligand for the NK cell activating receptor NKG2D. Similarly, it has been 
illuminated that the killing of YAC1 cells by influenza infected NK cells was down- 
regulated compared to uninfected NK cells 245. Taken together, it has been agreed that 
direct influenza virus infection can decrease NK cells cytotoxic potential. This can 
explain the low efficiency of viral clearance, despite the fact that vavFLIPR mice have a 
higher number of NK cells. Moreover, a higher level of proinflamatory cytokines, as 
well as a higher level MIP-1α and RANTES were observed in vavFLIPR mice at the 
peak of the influenza infection. Many types of cytokines and chemokines are produced 
in response to influenza virus infection 273. The connection between a strong immune 
response and severe disease following influenza virus infection in humans and animal 
models has been shown previously 274. In the early stage of influenza virus infection, 
cytokines and chemokines have a protective role for the host. However, this shifts to a 
pathogenic role in the later stage of infection 206,275,276. TNF-α is known to inhibit 
influenza virus replication and limit the spread of the virus 277. However, several studies 
have been demonstrated the pathogenic roles for TNF-α during influenza virus infection 
276. It has been shown that using anti-TNF-α antibody in mice resulted in reduction of 
inflammatory cells recruitment, T cell cytokine production and subsequently higher 
morbidity in influenza infected mice 278. Interestingly, no difference was observed in 
disease severity in mice deficient in TNFR1 or in both TNFR1 and TNFR2, following 
H5N1 infection 279. Notably, mice that lack both IL-1R and TNFR displayed reduced 
cytokine production and morbidity compared to WT mice 280. The reason for these 
disparate results can be the influenza virus strain or other unknown factors. 
Antiviral activity of IFN-γ has been demonstrated for many years. In the early phase of 
influenza infection, IFN-γ is mainly produced by macrophages and natural killer cells, 
while after day 5 post infection CD4+ and CD8+ T cells are the main source of IFN-γ. 
IFN-γ treatment at early stages of influenza infection has been demonstrated to protect 
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mice from death 205. Similarly, use of an agonist against the proteinase-activated 
receptor 2 (PAR2) in vivo, which increased IFN-γ production, was able to reduce 
influenza virus titer in comparison to infected WT mice 281. However, several studies 
have reported that following influenza infection, virus clearance is comparable in IFN-γ 
deficient and WT mice 282–284. NK cells secrete different anti-viral cytokines and pro-
inflammatory chemokines during influenza infection 140,215,245. Secretion of IFN-γ, TNF-
α, MIP-1α, MIP-1β and RANTES has been demonstrated to decrease in PR8 infected 
NK cells 245. This impairment of cytokine and chemokine secretion could be due to 
decreased ability of the PR8-infected NK cells to produce or secrete the cytokines and 
chemokines. Analyzing the levels of intracellular IFN-γ production in influenza infected 
NK cells revealed that IAV infection impaired generation of cytokines and chemokines 
248,285. Taken together, a comparison of the results in this thesis and other studies 
suggested that influenza-infected NK cells have less activity. Notably, the outcome can 
be different depending on the infection viral dose. The underlying mechanisms remain 
to be investigated. 
 
4.6. Concluding remarks 
The tight regulation of apoptosis is pivotal for multicellular organisms. Impaired 
apoptosis may result in cancer, autoimmune diseases, and developmental disorders. 
Cellular-FLIP proteins inhibit apoptosis directly at the death-inducing signaling 
complex of death receptors and play a role in apoptosis regulation during immune 
responses. 
Influenza virus is the prototypic member of the orthomyxoviridae family. The severity 
of influenza A virus infection is also closely linked to the dysfunction of apoptosis 
regulation. 
The physiological role of the c-FLIPR isoform in influenza virus infection was 
investigated in this thesis. Considering the data presented herein, mice with constitutive 
expression of c-FLIPR in all the hematopoietic cells were more susceptible to influenza 
virus infection. vavFLIPR mice had a higher number of NK cells at the peak of infection 
compared to WT mice. However, delayed viral clearance in vavFLIPR mice compared 
to WT mice was observed. Further in vitro study uncovered that murine NK cells are 
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susceptible to influenza virus infection. Additionally, it was demonstrated that influenza 
virus can replicate in primary murine NK cells. NK cells in vavFLIPR mice are more 
resistant to apoptosis. Less apoptosis in NK cells provided a reservoir for influenza 
virus to replicate in higher extent. It was concluded that early apoptosis occurring 
during influenza infection is supporting viral clearance. 
These findings suggested that the influenza virus may have developed multiple 
strategies including infecting NK cells to evade NK cell innate immune defenses, which 
mediate viral transmission and may also contribute to pathogenesis. 
Taken together, this thesis gives evidence for the hypothesis that NK cells can cause 
pathogenicity during viral infection. These findings underline the importance of strict 
regulation of apoptosis in immunity against viral infections. 
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5. Abbreviations 
 
APAF1 Apoptotic peptidase activating factor 1 
BAD BCL-2 associated of cell death 
BAK    BCL-2-antagonist/killer-1 
BAX   BCL-2-associated X protein 
BCA    Bicinchoninic acid 
BCL B-cell lymphoma 
BCL-2 B-cell lymphoma-2 
BCL-W B-cell lymphoma-2-like-2 
BCL-XL       B-cell lymphoma-extra-large protein 
BH BCL-2 homology domain 
BID BH3-interacting domain death agonist 
BIK BCL-2-interacting killer 
BIM   BCL-2 interacting mediator of cell death 
CARD Caspase recruitment domain 
CD95L CD95 ligand 
cFLIP Cellular FLIP 
cFLIPL Cellular FLIP long 
cFLIPR Cellular FLIP Raji 
cFLIPS          Cellular FLIP short 
CTL Cytotoxic T lymphocyte 
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CMV    Cytomegalovirus 
DC Dendritic cell 
DD               Death domain 
DED   Death effector domain 
DLN    draining lymph node 
DISC Death-inducing signaling complex 
DLN Draining Lymph node 
FACS Fluorescence-activated cell sorting 
FADD   Fas-Associated Death Domain 
FLICE FADD-like IL-1β-converting enzyme 
FLIP FLICE-inhibitory protein 
HA Hemagglutinin 
IAV Influenza A virus 
IFN Interferon 
i.n.                 Intranasal 
i.p.                 Intraperitoneal 
MHC   Major histocompatibility complex 
NK Natural killer 
NCR Natural cytotoxicity receptor 
NA Neuraminidase  
OMM Outer mitochondrial membrane 
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PAMP Pathogen associated molecular patterns 
pDC   plasmacytoid dendritic cell 
PBS   Phosphate buffered saline 
PCR Polymerase chain reaction 
p.i. Post infection 
qRT-PCR       Quantitative real-time polymerase chain reaction 
TNF tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
TRAILR TNF-related apoptosis-inducing ligand receptor 
UBC Ubiquitin-conjugating enzyme E2D 2A 
WT Wild type 
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